 
 
PROTOCOL  
The Restoring Insulin Secretion (RISE) Study  
RISE Adult Medication Study  
 
 
 
 
 
RISE Study Group  
Date:  August [ADDRESS_386517]  
Rockville, Maryland [ZIP_CODE]  
 
 
 
 
RISE Adult Medication  Protocol   Page 2 
 
 CONFIDENTIAL  TABLE OF CONTENTS  
1 Executive Summary  ................................ ................................ ................................ ...............................  7 
1.1 Specific Aims and Objectives  ................................ ................................ ................................ ........  8 
1.2 Overall Design and Study Interventions  ................................ ................................ .......................  9 
2 Background and Significance  ................................ ................................ ................................ ..............  10 
2.1 Prediabetes and Type 2 Diabetes: Epi[INVESTIGATOR_623], Natural History and Pathogenesis  ................  10 
2.2 Obstructive Sleep Apnea (OSA) and Diabetes Risk  ................................ ................................ ..... 11 
2.3 Results of Type 2 Diabetes Prevention Studies  ................................ ................................ ..........  11 
2.4 Long Term Intervention Studies in Patients with Early Type 2 Diabetes  ................................ .... 12 
2.5 Metformin  ................................ ................................ ................................ ................................ ... 14 
2.6 Insulin Glargine  ................................ ................................ ................................ ...........................  15 
2.7 Liraglutide  ................................ ................................ ................................ ................................ ... 15 
2.8 Approaches to Measuring ß -cell Function, -cell Function, Insulin Sensitivity and Glucose 
Tolerance  ................................ ................................ ................................ ................................ ................  16 
2.8.1  Intravenous Tests of ß - and -cell Function and Insulin Sensitivity  ................................ .......  16 
2.8.2  Oral Tests of ß - and -cell Function and Insulin Sensitivity  ................................ ....................  18 
2.9 Biomarkers of ß -cell Function, -cell Function, Insulin Sensitivity and Glucose Tolerance  ...... 18 
2.9.1  Putative Diabetes Biomarkers  ................................ ................................ ................................ . 19 
3 STUDY DESIGN ................................ ................................ ................................ ................................ ..... 19 
3.1 Overview and Rationale  ................................ ................................ ................................ ..............  19 
3.2 Primary Outcomes  ................................ ................................ ................................ ......................  21 
3.3 Secondary Outcomes  ................................ ................................ ................................ ..................  21 
3.3.1  ß-cell Function and Glucose Tolerance  ................................ ................................ ...............  22 
3.3.2  -cell Function  ................................ ................................ ................................ ....................  [ADDRESS_386518] -treatment Follow Up  ................................ .......................  25 
3.4.8  Rescue  ................................ ................................ ................................ ................................ . 26 
3.5 Inclusion Criteria  ................................ ................................ ................................ .........................  26 
3.6 Exclusion criteria  ................................ ................................ ................................ .........................  26 
3.7 Randomization  ................................ ................................ ................................ ............................  28 
3.8 Masking  ................................ ................................ ................................ ................................ .......  28 
4 RECRUITMENT  ................................ ................................ ................................ ................................ ..... 28 
4.1 Recruitment  ................................ ................................ ................................ ................................  28 
4.2 Description/Justification of the Target Study Population  ................................ ...........................  29 
4.3 Informed Consent  ................................ ................................ ................................ .......................  30 
4.4 Stag ed Screening and Randomization  ................................ ................................ ........................  30 
5 PATIENT MANAGEMENT  ................................ ................................ ................................ .....................  32 
5.1 Description of RISE Research Facility Treatment(s)  ................................ ................................ .... 32 
5.2 Drug Distribution  ................................ ................................ ................................ .........................  32 
5.3 Adherence Measures  ................................ ................................ ................................ ..................  33 
RISE Adult Medication  Protocol   Page 4 
 
 CONFIDENTIAL  5.3.1  Placebo Run -in ................................ ................................ ................................ ....................  33 
5.3.2  Liraglutide  ................................ ................................ ................................ ...........................  33 
5.3.3  Insulin  ................................ ................................ ................................ ................................ .. 34 
5.3.4  Metformin/Placebo  ................................ ................................ ................................ .............  [ADDRESS_386519] (OGTT)  ................................ ................................ ...................  [ADDRESS_386520] -Randomization Measures  ................................ ................................ ..............  37 
6.3.1  Physical Measures  ................................ ................................ ................................ ...............  38 
6.3.2  Sleep Assessments  ................................ ................................ ................................ ..............  39 
6.3.3  Safety Measures  ................................ ................................ ................................ ..................  39 
6.3.4  Participant Protocol Adherence  ................................ ................................ ..........................  39 
6.4 Visit Windows  ................................ ................................ ................................ .............................  39 
7 SAFETY / HUMAN SUBJECTS PROTECTION  ................................ ................................ .........................  [ADDRESS_386521] (DSMB)  ................................ ................................ ................  40 
7.2 Data and Safety Monitoring Plan  ................................ ................................ ................................  40 
7.2.1  Informed Consent  ................................ ................................ ................................ ...............  40 
7.2.2  Safety Review Plan and Monitoring  ................................ ................................ ....................  40 
7.2.3  Confidentiality  ................................ ................................ ................................ .....................  41 
7.3 Expected Side Effects  ................................ ................................ ................................ ..................  41 
7.4 Risk Management  ................................ ................................ ................................ .......................  42 
RISE Adult Medication  Protocol   Page 5 
 
 CONFIDENTIAL  7.5 Pote ntial Benefits  ................................ ................................ ................................ ........................  45 
7.6 HIPAA – Protection of Patient Information ................................ ................................ .................  45 
8 ADVERSE EVENT REPORTING  ................................ ................................ ................................ ..............  45 
8.1 Definition of Serious Adverse Events  ................................ ................................ ..........................  46 
8.2 Non -serious Adverse Events  ................................ ................................ ................................ .......  46 
8.3 Reporting Adverse Events  ................................ ................................ ................................ ...........  46 
8.4 Tracking Adverse Events  ................................ ................................ ................................ .............  47 
8.5 Emergency Unmasking  ................................ ................................ ................................ ................  47 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ...........  47 
9.1 Primary Outcome and Analyses  ................................ ................................ ................................ .. 48 
9.2 Secondary Outcomes and Analyses  ................................ ................................ ............................  48 
9.3 Sample Size/Power Calculations  ................................ ................................ ................................ . [ADDRESS_386522] in  the pathogenesis of type 2 diabetes involves the ß -cell, which has been shown 
to be dysfunctional in both prediabetes, a high risk state  that is antecedent to type 2 diabetes , 
and established type 2 diabetes [1]. In addition to ß -cell f ailure, insulin resistance and -cell 
dysfunction are prominent features of the disease  leading to diabetes onset  [1, 2].  
The possibility that improvements in ß -cell function in type 2 di abetes can be achieved and 
maintained for a period of time after withdrawal of a dietary or pharmacological intervention 
has been suggested by [CONTACT_313974] , oral hypoglycemic drugs and diet [3-5]. 
However, it is unclear whether any beneficia l effect on ß -cell function can be maintained and 
the natural history of progressive loss of ß -cell function altered. Further, while these studies 
focused on the ß -cell, they did not consider the possibility that producing a sustained 
improvement in -cell function may also be important in slowing progression of glucose 
intolerance.  
Numerous medications, acting by [CONTACT_129427], are available to treat type 2 diabetes 
and lower blood glucose. Metformin is thought to reduce hepatic glucose production a nd 
improve insulin resistance; it has been shown to prevent progression of prediabetes to diabetes 
[6]. Insulin lowers glucose while providing ß -cell “rest”. Insulin sensitizers may improve ß -cell 
function indirectly by [CONTACT_175404] ß -cell stress [7, 8]. Sulfonylureas initially improve ß -cell function 
but may accelerate secondary failure [7, 8]. Glucagon -like peptide -1 receptor agonists (GLP -
1RA) and other incretin -based therapi[INVESTIGATOR_313948]  [9, 10], but their ability to 
prevent diabetes and slow its progression is unknown.  
The RISE (Restoring Insulin Secretion) Study consortium is comprised of seven clinical cente rs. 
Investigators at these centers will conduct three different protocols to assess the feasibility of 
different interventions in adults and children to preserve or improve ß -cell function in 
individuals with prediabetes or recent -onset type 2 diabetes.  Three adult centers (the topic of 
research supported by [CONTACT_3181]) will together perform a randomized, partially blinded, 
placebo -controlled trial comparing three treatment regimens versus placebo. The three 
treatment regimens are: (1)  metformin  alone , (2) early intensive insulin treatment with insulin 
glargine (Lantus®) followed by [CONTACT_14424], or  (3) the GLP-1RA liraglutide (Victoza®) plus 
metformin . These adult centers are located at the VA Puget Sound Health Care System / 
University of Washington, Univ ersity of Chicago  / Jesse Brown VA  Medical Center , and Indiana 
University. In addition to this 3 -center adult study, four  centers will participate in a pediatric 
study performing a randomized trial comparing metformin with insulin glargine (Lantus®) 
follow ed by [CONTACT_14424] . These centers are located at the University of Colorado, University of 
RISE Adult Medication  Protocol   Page 8 
 
 CONFIDENTIAL  Pi[INVESTIGATOR_9109], Yale University and Indiana University. One additional adult center at the University 
of Southern [LOCATION_004] will perform a randomized trial comparing the e ffects  of gastric band 
obesity surgery  to metformin on ß-cell function. The three protocols will use many of the same 
inclusion and exclusion criteria, study procedures, timeline and outcome measures to allow for 
comparisons among  groups and interventions.  The overall goal of each active intervention is to 
reduce glucose levels to near normal during a 12 -month treatment period and determine 
whether this slows deterioration or induc es recovery of ß - and -cell function and produces a 
prolonged remission , i.e. sustained improvement in islet function that is associated with 
improved glycemia after the intervention has been discontinued . 
This protocol describes the study that will be performed at three centers in adults.  
1.[ADDRESS_386523] -challenge glucose levels along with elevations in 
hemoglobin A1c and/or  fasting  glucose concentrations. The hypoth esis is that , in participants  
with prediabetes or recent -onset  type [ADDRESS_386524] identified th e following  
primary and secondary specific aims.  
The primary specific aim  is to determine whether:  
 Functional improvements in ß -cell function following 1 2 months of active treatment  
with  (1) metformin alone  for 12 months, (2) insulin glargine short term (3 months) 
followed by [CONTACT_313975] 9  months , or (3)  the combination of liraglutide  plus 
metformin for [ADDRESS_386525] 3 months following the 
withdrawal of therapy , compared to placebo . 
The secondary specific aims  are to determine in this same cohort whether:  
 Treatment  with the intervention therapi[INVESTIGATOR_53301] 12 months improves ß -cell function 
compared to placebo ,  
 Functional improvements in ß-cell function are maintained for 9 months  following th e 
withdrawal of therapy , compared to placebo,  
RISE Adult Medication  Protocol   Page 9 
 
 CONFIDENTIAL   Treatment with the intervention  therapi[INVESTIGATOR_53301] 1 2 months improves -cell function 
compared to placebo, and whether this improvement is maintained after withdrawal of 
therapy,   
 Measures of ß - and -cell function from an oral glucose tolerance test ( OGTT ) and 
fasting samples made on and off therapy are sufficiently well correlated with more 
robust and technically demanding assessments , validating use of the simpler measures  
in large clinical trials, and 
 Biomarkers obtained at baseline  can predict parameters of ß - and -cell function, insulin 
sensitivity and glucose tolerance and the response to an intervention.  
1.2 Overall Design and Study Interventions  
The RISE Adult Medication S tudy is a preliminary pro of-of-principle , four -arm, partially double -
blind study in which volunteers with prediabetes or drug -naïve, recent onset  type 2 diabetes 
(HbA1c ≤7%, fasting glucose 95-125 mg/dl, and 2 -hour glucose ≥140 mg/dl post 75 gram oral 
glucose challenge) are random ized to: (1) metformin alone, (2) short -duration insulin glargine 
followed by [CONTACT_14424] , (3) liraglutide  plus metformin , or (4) metformin placebo. The study will 
recruit participants  over a three -year period and follow them  for a total of [ADDRESS_386526] -trial analysis and reporting.  
ß-cell func tion, -cell function, insulin sensitivity and glucose tolerance will be assessed using 
intravenous and oral tests. Both intravenous and oral tests will be obtained at baseline, after 12 
months of therapy and at 15 months ( 3 months after treatment has been  stopped) . In addition, 
oral tests will be done at 6 months  on therapy, and 9 months off treatment. From these 
intravenous and oral tests as well as  fasting measures , we will assess the sustainability of 
induced improvements and determine how well simpler measures of ß-cell function, -cell 
function and insulin sensitivity correlate with  more sophisticated measures. Finally, a series of 
biomarkers will be measured to determine whether they predict ß - and -cell function, insulin 
sensitivity and glucose tole rance , and/or  well as the resp onse to therapy .  
This study  will provide critical  information about the ability of early aggressive treatment 
approach es to lead to sustained recovery of islet function, and whether such approaches 
should be studied in  larger  clinical trials. Further, t his study  will provide valuable information 
regarding the potential use of simpler measures of glucose metabolism as well as biomarkers 
that can be used in  future clinical studies and , ultimately , in routine clinical care.  
RISE Adult Medication  Protocol   Page 10 
 
 CONFIDENTIAL  2 Background and  Significance  
2.1 Prediabetes and Type 2 Diabetes: Epi[INVESTIGATOR_623], Natural 
History and Pathogenesis   
The increasing prevalence of obesity has been associated with a relentless rise in the 
prevalence of diabetes and prediabetes (impaired glucose tol erance [IGT] and/or impaired 
fasting glucose [IFG]). In the [LOCATION_002] , there are currently nearly 26 million people , or 
11.3% of the population aged 20 years or older , with diabetes ; the incidence is estimated at 1.9 
million new cases annually [11]. Over 90 percent of these cases are due to type 2 diabetes. In 
addition, approximately 79 million , or 35% of the same age group , have prediabetes [11]. While 
both diabetes and prediabetes are defined by [CONTACT_313976]/or 2 -hour plasma 
glucose [12] or HbA1c [13], one can consid er the disorders a continuum  of progressive 
dysglycemia . Individuals with prediabetes are at very high risk of developi[INVESTIGATOR_303729] [6, 14-16], 
while those with established diabetes exhibit a  progressive loss of glucose control [17].  
The pathogenesis of diabetes and prediabetes involves two major defects: insulin resistance 
and ß -cell dysfunction [1, 18]. Although improvements in insulin sensitivity can slow 
progression of both disorders, ultimately, progressive  ß-cell dysfunction is critical for both the 
development [19] and progression [8] of type [ADDRESS_386527] in the ability of the ß cell to efficiently process 
proinsulin to insulin [1, 20]. 
The progressive loss of the ability to release  insulin determines the deterioration  of glycemia 
[18, 21, 22], and thereby [CONTACT_313977] a vicious cycle in which the metabolic derangements 
(“glucolipotoxicity”) associated with type 2 diabetes beget further ß -cell dysfunction [23]. In 
addition to ß -cell dysfunction, ß -cell volume (“mass”) is reduced in type 2 diabetes and possibly 
in those with prediabetes [24-26]. This loss of ß -cells may result from or be accelerated by 
[CONTACT_313978] [23] and other abnormalities such as amyloid deposition that impact the islet 
[27]. 
Aside from the ß -cell lesion, a functional abnormality of the islet -cell also contributes to 
hyperglycemia  in type 2 diabetes  [2, 28, 29]. While fasting glucagon levels may or may not be 
elevated [2], normal suppression of glucagon following oral nutrient ingestion does not occur ; 
rather a paradoxical increase in glucagon levels can occur [2, 28, 29]. Further, during 
hyperglycemic cl amps, glucagon release is greater in patients with type 2 diabetes than in 
healthy subjects [30]. Finally, -cell dysfunction is prese nt in subjects with IGT [31, 32] and f irst-
RISE Adult Medication  Protocol   Page 11 
 
 CONFIDENTIAL  degree relatives of individuals with type 2 diabetes [33], both groups at increased risk of 
developi[INVESTIGATOR_36746] 2 diabetes. Thus, -cell dysregulation appears to also be an early feature of the 
islet lesion  in patients with type 2 diabetes and those at high risk .  
2.2 Obstructive Sleep  Apnea (OSA) and Diabetes Risk  
The alarming increase in overweight and obesity plays a pi[INVESTIGATOR_313949]. The obesity epi[INVESTIGATOR_313950], a 
treatable sleep disorder involving shallo w and fragmented sleep as well as intermittent hypoxia. 
OSA is a well -documented risk factor for glucose intolerance, insulin resistance and diabetes, 
independently of body mass index  [34, 35]. Further,  studies have sh own that OSA is a frequent 
co-morbidity of diabetes with a prevalence averaging 68%  [36-38]. To date, however, clinical 
trials in individuals with prediabetes or diabetes have not taken  the presence and severity of 
this co -morbidity into account. Thus, we will make assessments of sleep by [CONTACT_313979] ß- and/or -cell function  over 
time or the impact of the glucose -lowering intervention.  
2.[ADDRESS_386528] success has been ach ieved with the three thiazolidinediones 
(TZDs ) which in TRIPOD ( Troglitazone In the Prevention o f Diabetes) , DPP ( Diabetes  Prevention 
Program), DREAM ( Diabetes  Reduction Assessment with Ramipril and Rosiglitazone Medication)  
and ACT NOW ( Actos Now for Prev ention of Diabetes)  reduced  the short -to-intermediate risk of 
deterioration in glycemic control by  55-72% [15, 39-41], rates similar to or greater than the 58% 
risk reduction  observed with lifestyle interventions in the DPP and FDS (Finnish Diabetes 
Prevention Study)  [6, 14, 39]. The DPP also demonstrated that  metformin  reduced the risk of 
progression to diabetes by 31% over three years  [39]. Other large studies examining the effects 
of medications show ed that acarbose in STOP -NIDDM  decreased the risk by 25%  [42], but the 
ß-cell secretagogue nateglinide did not reduce the risk of progression to diabetes in 
NAVIGATOR ( Nateglinide And Valsartan in Impaired Glucose Tolerance Out comes Research)  
[43]. The ORIGIN  (Outcome Reduction With Initial Glargine Intervention ) study  showed that  
insulin glargine reduced the risk of developi[INVESTIGATOR_313951] 28% while participants were on 
therapy, and by 20% 100 days after withdrawal of therapy [44]. 
Medication c ombination s have had variable effects, with low dose rosiglitazone plus metformin 
in CANOE ( Canadian Normoglyc emia Outcomes Evaluation ) producing a c omparable effect to 
that reported in other studies where larger doses of a TZD were used  [45]. Of relevance  to RISE , 
no studies of diabetes prevention have yet been reported with incretin -related medications  
RISE Adult Medication  Protocol   Page 12 
 
 CONFIDENTIAL  alone or in combination with other approaches . 
Follow up after discontinuation of the intervention , with the aim of assessing the durability of 
the intervention effects  has only been undertaken in a few instances. In the FDS, withdrawal of 
the lifestyle intervention was associated with continued risk r eduction three years later [46]. In 
DREAM On, after withdrawal of rosiglitazone, the annual incidence of diabetes was sim ilar in 
those who were or were not randomized to receive the medication, while the cumulative 
incidence in those previously exposed to active medication remained lower ; this observation 
suggests a delay but not a reversal of the underlying disease process [39, 47, 48]. To date there 
has not been a systematic evaluation to determine whether interventions can slow the 
progression to d iabetes by [CONTACT_313980], particularly that of decline 
in ß-cell function.  
2.[ADDRESS_386529] been  relatively short in duration (6 -12 months) and 
follow up has typi[INVESTIGATOR_313952]. Importantly, with the exception of the [LOCATION_006]PDS (United Kingdo m Prospective 
Diabetes Study) and ADOPT ( A Diabetes Outcome Progression Trial) , long -term effects  of 
diabetes treatments  on ß -cell function have  not been determined.  
In the [LOCATION_006]PDS, patients with recently diagnosed diabetes received “intensive” treatment wit h a 
sulfonylurea, insulin [17] or metformin [49] for an average of [ADDRESS_386530] year, 
fasting glucose and HbA1c increased at similar rates in both the “intensive” and  “conventional” 
treatment group s, firmly establishing the progressive nature of the disease [17, 49]. This 
deterioration in both groups was shown to be due to relentless ß -cell failure [50]. Why insulin 
did not prevent progression of ß -cell dysfunction is unclear, but may be because HbA1c was not 
reduced to near normal  levels , reaching a  nadir of about 6.4% at the end of the first year o f 
treatment.  
The findings in the [LOCATION_006]PDS  contrast with those of other studies  in which  short -term treatment 
with  multiple daily insulin injections (MDI) or  continuous subcutaneous insulin infusion ( CSII) 
improved ß -cell function after fasting glucose was nor malized [3-5]. The largest of these studies 
was performed in 382 Chinese adults with fasting plasma glucose levels of >126 mg/dl who 
were randomly assigned to therapy with insulin ( MDI or CSII ) or oral glucose -lowering  
medications  in order to rapid ly correct the elevated glucose and maintain it in the normal range 
for two weeks. Patients were subsequently prescribed diet and exercise alone  and followed for 
RISE Adult Medication  Protocol   Page 13 
 
 CONFIDENTIAL  a year . More subjects  in the two insulin groups achieved the target glycemic level  and did so in 
less time than those using oral agents. Remission rates after one  year w ere significantly higher 
in the insulin groups (51.1% in CSII and 44.9% in MDI) than in the group taking oral glucose 
lowering therapy (26.7%; p=0.0012). ß -cell function in the remission group, determined by 
[CONTACT_14785]  B (homeostatic  model  assessment  ß-cell inde x) and the acute insulin response to 
glucose, improved significantly after the intensive interventions, and was better sustained in 
the insulin groups after one year.  
ADOPT compared rosiglitazone, metformin and glyburide in patients with recently diagnosed  
(<3 years) diabetes [7]. Over a median of four  years, rosiglitazone reduced the progression of 
hyperglycemia more effectively than did glyburide, with metformin being intermediate  in its 
effect . The glyburide -induced increase in secretory output was associated with a more rapid 
loss of ß -cell function than “resting” the ß -cell by [CONTACT_313981] [7, 8]. Importantly, patients who progressed to monotherapy failure had higher 
fasting glucose and HbA1c levels and lower ß -cell function at baseline, and demonstrated the 
most marked decline in ß -cell function irresp ective of treatment assignment [8]. The use of 
rosiglitazone has since been severely restricted by [CONTACT_941] U.S. Food and Drug Administration (FDA) 
because of concerns about associated cardiovascular events. The other  TZD, pi[INVESTIGATOR_051], 
remains available but has been associated with bladder cancer [51, 52]. In addition, this class of 
drugs has been associated with weight gain, edema and fr actures [7], side effects that f urther 
limit the attractiveness of these drugs in individuals early in the course of disease.  
Incretin -based therapi[INVESTIGATOR_313953]. They not only increase insulin secretion and decrease glucago n release, but also 
preserve the morphology of cultured human islets [53] and increase ß -cell mass following 
partial pancreatectomy in rodents [54]. In humans, long -term intervention studies with these 
agents are limited. The only study examining the potential for durability compared the effect of 
three years of treatment with the GLP -1RA exenatide to insulin glargine in a small number of 
patients who were also taking metformin. HbA1c (7.4 -7.6% at baseline) was reduced similarly in 
both groups to 6.7 -6.8% after one year of therapy  in 69 participants , with the exenatide group 
demonstrating improved ß -cell function while the insulin glargine group showed no change. 
Follow ing one month of washout, ß -cell function was similar to pretreatment values in both 
groups [55]. Thereafter,  therapy was restarted  in a subgroup, and was continued to three years  
in 36 participants,  at which  point  medication was withdrawn for one month. Better  ß-cell 
function was observed in those treated with  exenatide, in keepi[INVESTIGATOR_18499] a benefit beyond the 
period of exposure [56]. The magnitude of improvement was small, however, and It is unclear 
whether the need for prolonged therapy to demonstrate a benefit was be cause subjects had 
reasonably long standing diabetes with poor ß -cell function at baseline and/or the attained 
RISE Adult Medication  Protocol   Page [ADDRESS_386531] potential to induce prolonged remission will be with aggressive 
glucose lowering and in those with earlier disease and milder defects , possibly by [CONTACT_175404] ß -
cell burden to produce and release insulin . This is supported by [CONTACT_313982] (a) in 
ADOPT those who did not progress to monotherapy fail ure had lower glucose levels and better 
ß-cell function at baseline , (b) the greatest success in slowing progression in those with 
prediabetes and early diabetes occurred with TZDs, which reduce ß -cell secretory demand,  and 
(c) the beneficial effect of exe natide was observed after prolonged therapy in individuals with 
well established diabetes in whom glucose levels were not near normal  at baseline or during 
therapy . 
Thus, we propose to study subjects with prediabetes or early diabetes who at baseline will have 
better ß -cell function than those with a longer duration of diabetes. W e will use therapeutic 
approaches that aim to lower glucose to levels that are close to normal using approaches that 
will either increase ß -cell responsiveness or decrease secretor y demand on the ß -cell and 
compare them to placebo . 
2.[ADDRESS_386532], in the 
DPP it was documented that the improvement in insulin sensitivity associated with metformin 
treatment resulted in a decrease in secretory demand and , thus , insulin relea se by [CONTACT_941] ß -cell 
[19]. In addition to its glucose lowering action, an added potential benefit of metformin is a 
modest weight loss, and some protection from weight gain with other diabetes treatments 
including insulin [57, 58]. Metformin is not currently approved for use in the prevention  of type 
2 diabetes.  However, the DPP demonstrated that metformin is effective in persons with 
impaired gl ucose tolerance, reducing the development of diabetes by 31%  [6]. 
The most common side effects associated with metformin are gastrointestinal. As many as 30% 
of persons report diarrhea, nausea, metallic tas te, abdominal bloating, flatulence or anorexia . 
These symptoms are generally transient, resolve spontaneously and can be avoided by [CONTACT_313983].  About 4% of participants were unable to continue metformin in U.S. 
clinical trials.  Metformin is not associated with hypoglycemia unless used in conjunction with 
other glucose -lowering medications (sulfonylurea or insulin) . Metformin has been found to 
rarely cause lactic acidosis (about 0.03 cases per 1,000 person years), and then only when used 
RISE Adult Medication  Protocol   Page 15 
 
 CONFIDENTIAL  in persons with renal or hepatic insufficiency or during epi[INVESTIGATOR_313954]  
[57].  
2.[ADDRESS_386533] ant profile over 24 hours. It has been used 
since 2000 to treat patients with type 2 diabetes and has recently been reported to reduce the 
risk of developi[INVESTIGATOR_36746] 2 diabetes in individuals  with prediabetes  by 28% [44]. Insulin g largine 
administered at night lowers plasma glucose by [CONTACT_313984]  [59] and 
can be titrated in individuals with prediabetes and established diabetes to achieve fasting 
glucose concentrations of <95 mg/dl  without a marked increase in recurrent or severe 
hypoglycemia  [44]. 
The most common side effects observed with insulin glargine are hypoglycemia and weight 
gain. This insulin has been reported in some non-randomized, epi[INVESTIGATOR_313955]  [60]. However , ORIGIN, a randomized trial in which 
over 6,000 participants received insulin glargine for a median of 6.2 years, did not observe an 
association between insulin glargine and cancer [44]. 
2.7 Liraglutide  
Liraglutide is an acylated human GLP -1RA with 97% amino acid sequence homology to the 
endogenous form of GLP -1(7-37). It was approved for use in type 2 diabetes in 2009. 
Liraglutide , like other GLP -1RAs,  increases intracell ular cyclic AMP in ß-cells leading to insulin 
release in the presence of elevated glucose concentrations ; thus , insulin secretion subsides as 
blood glucose decreases and approaches euglycemia  [10]. The clinical implication of this is that 
hypoglycemia is infrequent when liraglutide is combined with agents other than sulfonylureas 
or insulin . Liraglutide also decreases glucagon secre tion in a glucose -dependent manner, but 
does not limit the -cell’s response to hypoglycemia. The mechanism of blood glucose lowering 
may also involve a delay in gastric emptying. Unlike native GLP -1, liraglutide is stable against 
metabolic degradation by [CONTACT_36273] -4 (DPP-4) and neutral endopeptidases.  
ß-cell function in patients with type 2 diabetes is enhanced by [CONTACT_313985]  [61]. In animal studies, beneficial effects 
on ß -cell mass have also been observed, but such an effect in humans has not been 
demonstrated. Liraglutide is also associated with reductions in  body weight.  
RISE Adult Medication  Protocol   Page [ADDRESS_386534] been reported to be 
associated with an increased risk of pancreatitis, the mechanism for which is unclear  [62]. This 
adverse effect occurs on a background of an increased risk of pancreatitis in patients with type 
2 diabetes  [63]. In rodent studies, liraglutide has been found to cause thyr oid C -cell tumors; 
however, it has not been established that this occurs in humans  [62]. Given the above, 
liraglutide should not be used  in patients with a history of pancreatitis,  a personal or family 
history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia 
syndrome type 2.  
2.8 Approaches to Measuring ß -cell Function, -cell Function, 
Insulin Sensitivity and Glucose Tolerance  
Glucose homeostasis is physiologically modulated under fasting and prandial conditions by a 
number of regulatory factors, most prominently insulin and glucagon. Measurements made 
under fasting conditions are generally proportional to direct measures of the dynamic 
responses, but the most rigorous measure ment of ß -cell function (insulin and/or C -peptide 
response s to physiologic stimuli) comes from evaluation of dynamic tests. Dynamic testing can 
be accomplished with oral intake of glucose or mixed meals, or with intravenous infusion of 
glucose or other ß -cell stimulators . In RISE, t he hyperglycemic clamp technique  will be used  to 
examine insulin sensitivity and ß-cell function, and the OGTT will be used as a complementary 
measure that more closely reflects the integrated physiologic response to ingested sti muli , 
including incretins . 
2.8.1 Intravenous  Tests of ß - and -cell Function and Insulin Sensitivity  
Glucose tolerance is dependent on ß -cell function and insulin sensitivity, and both of these can 
be quantified using the hyperglycemic clamp  [64]. The role of -cell function in determining 
glucose tolerance is less well defined.  
The acute insulin (C-peptide) response to intravenous glucose (AIRg or first phase insulin 
response) occurs within the  first ten minutes following bolus glucose administration and is a 
sensitive marker of ß -cell function that decreases as the fasting glucose level rises. A potential 
“drawback” of this measure is that the first phase response drops sharply as the fasting g lucose 
level approaches 115 mg/dl  [65]. Above that level, the first -phase response is markedly 
diminished and frequently absent. Although this early response may respond to treatment 
interventions aimed at restoring or preserving ß -cell function  in some patients , this d efect, in 
the absence of medication, appears particularly resistant to reversal. The response is possibly 
RISE Adult Medication  Protocol   Page 17 
 
 CONFIDENTIAL  related to the type of intervention used to bring about improvement in ß -cell function. T hese 
difficulties with measuring early responses at baseline limit our ability to depend on this 
measure of ß -cell function as a  primary  outcome in RISE.  
The second  phase insulin response to intravenous glucose begins at the time of glucose 
administration and continues for as long as the glucose level remains elevat ed. It is frequently 
quantified as part of a hyperglycemic clamp. Unlike the acute insulin response to glucose, the 
second phase response persists and is measurable even when the fasting glucose concentration 
exceeds 115 mg/dl  [66]. Moreover, it is  proportional to overall ß-cell secretory  capacity and can 
be measurably improved with treatment interventions targeting ß -cell function  [67]. 
ß-cells also respond to non -glucose secretagogues, such as peptides and amino acids.  The 
prevailing glucose level modulates the ß -cell secretory response to non -glucose secretagogues. 
By [CONTACT_313986] a bolus intravenous arginine  injection , 
it is possible to quantify the maximum insulin response ( AIRmax ), which provides an estimate of 
the maximum ß-cell secretory capacity at a given point in time. In the absence of techniques 
that provide a direct measure of ß -cell mass in living humans, this  measure of maximal  
secretory capacity is currently taken as  an indirect measure of ß -cell mass. AIRmax is decreased 
in patients with type 2 diabetes [30] and in those at risk of developi[INVESTIGATOR_313956] [68]. Again , 
unlike the first phase response, AIRmax responses are present and readily quantif ied in 
individuals with higher fasting glucose levels (>115 mg/dl). Effects of treatment interventions 
on AIRmax have not been extensively evaluated but are beginning to be studied [56]. 
ß-cell responses also are modulated by [CONTACT_300119]. Therefore , expressing 
ß-cell function relative to insulin sensitivity provides a better estimate of how well the ß -cell is 
performing [69]. This approach of accounting for the effect of insulin sensitivity has been used 
extensively with AIRg derived from frequently sampled IV glucose tolerance tests, where the 
intravenous glucose tolerance test ( IVGTT )-derived measure of insulin sensitivity (S I) is used to 
produce the ‘disposition index’ (S I x AIRg) [69]. This approach can also be applied to adjust 
other measures of ß -cell function, providing that the underlying assumption of a hyperbolic 
relationship between the insulin  sensitivity  variable and the ß -cell function variable is true . 
Likewise, AIRmax can be adjusted for insulin sensitivity (e.g. S I x AIRmax; [69]). Insulin 
sensitivity -adjuste d ß-cell function measures derived from second phase responses and AIRmax 
responses measured with hyperglycemic clamp methods have been selected as the primary 
outcome measurements for RISE . 
The reciprocal of glucose’s ability to potentiate the ß -cell resp onse is its ability to suppress  
glucagon secretion from  the -cell. This function can also be measured using hyperglycemic 
clamps along with arginine  [30, 70]. The ability of glucose to suppress the acute glucagon 
RISE Adult Medication  Protocol   Page 18 
 
 CONFIDENTIAL  response  is impaired in people with type 2 diabetes  and in those with prediabetes , indicative of 
impaired -cell regulation [30, 71]. This parameter will be quantified using the hyperglycemic 
clamp  with arginine injection  (AGRmin, minimum acute glucagon response ) and, if funding is 
available,  will be analyzed as a secondary outcome in RISE.  
2.8.2 Oral  Tests of ß - and -cell Function  and Insulin Sensitivity  
The OGTT provides measures of islet function and has been used in large clinical trials for this 
purpose. The early insulin response (insulinogenic index) is an important determinant of 
glucose tolerance [18]. This response, when used in combination with a fasting measure of 
insulin sensitivity (1/fasting insulin, HOMA, or QUICKI) provides another estimate of ß -cell 
function termed the “oral disposition index ” (DIo) [22, 72]. However, the accuracy of HOMA in 
assessing changes in insulin sensitivit y over time may not be as reproducible and accurate  as 
clamp techniques [73]. Using modeling approaches such as those developed by [CONTACT_300120] . [74] 
and Cobelli et al . [75], it is possible to obtain a number of additional parameters of ß -cell 
function and insulin sensitivity  from the OGTT . In addition, using C-peptide levels and de -
convolution techniques, insulin secretion rates can be calculated from the OGTT [74-76] . 
Finally, overall glucose tolerance can be calculated from the glucose excursion during the test 
[77], providing a measure that is directly interpretable and applicable in the clinical setting . 
Physiological glucagon suppression during an OGTT is an important determinant of glucose 
tolerance and provides an estimate of -cell function. In individuals with type 2 diabetes, 
glucagon suppression is impaired [2, 28, 29], an abnormality t hat is improved with incretin -
based therapy [10]. However, whether this change persists after withdrawal of therapy is 
unknown.  
These OGTT -based measures will be performed in the study and their relationship with 
intravenous test-based measurements  will be determined , both at baseline and following drug 
interventions.   
2.9 Biomarkers of ß -cell Function, -cell Function, Insulin 
Sensitivity and Glucose Tolerance   
It is often the case that biologic phenomena of interest are both difficult and costly to measure 
directly. This can be true of physiologic states such as ß -cell function, but it is also true for time -
dependent changes such as rates of progression to overt diabetes. In these instances we turn to 
biomarkers. An optimal bioma rker is measured from a single  biological sample  (e.g., blood  or 
urine) and is less costly, less labor intensive and highly correlated with the result from  the 
process under evaluation . However , a biomarker might be the result of combinations of blood 
RISE Adult Medication  Protocol   Page 19 
 
 CONFIDENTIAL  tests, or measurements from other body fluids, or even measurements of other biological 
substances  [78].  
In RISE , treatments aimed at restoring or preserving ß -cell function  are being implemented and 
their effects determined  using  dynamic m easures of ß -cell function  discussed above . This 
provides the opportunity to concurrently attempt to identify biomarkers to assess islet function 
in relation to the systemic metabolic state, and to predict how these change over time. The 
identification of such biomarkers is an important ancillary goal of the project  since a practical 
application of strategies learned from this study will ultimately require a screening test to 
identify likely responders to the interventions.  
2.9.[ADDRESS_386535] deterioration of β -cell function and/or response to 
interventions that can mitigate such deterioration. The identification of such bi omarkers is an 
important ancillary goal of the RISE Consortium. Because of budget constraints, the focus 
during this stage of the project will be on collecting patient specimens that can used in the 
future for identification of biomarkers once the main out comes of the study are known. We will 
collect samples that can be used to examine previously described peptide markers of diabetes 
risk (e.g., adiponectin, ferritin, ApoB, C -reactive protein, IL -2 receptor A [79-82]) and evolving 
markers of ß -cell mass regulation (e.g., prolactin, DNA fragments and methylation, GLP -1, 
glucose -dependent insulinotropic peptide [ GIP], HSP90nucl eic acids [83-87]). We will also 
collect serum samples that can be analyzed using genomic, micro -RNA, proteomic and 
metabolomics approaches comparing for example responders to non -responders to the study 
interventions.   
3 STUDY  DESIGN  
3.1 Overview  and Rationale  
This document is specific for the RISE Adult Medication Protocol that three centers are 
performing  together in individuals with prediabetes or recent onset type 2 diabetes . This 
preliminary proof -of-principle  study is a randomized, partially blinded, placebo -controlled tri al 
comparing metformin  alone , insulin glargine followed by [CONTACT_14424], or liraglutide  plus 
metformin to placebo . The primary outcome is ß -cell function, measured as defined below.  
The RISE Adult Medication P rotocol will involve 2 55 adults age 20 -65 years o ld. Volunteers will 
be men and women with prediabetes or with drug -naïve, recent onset, mild type 2 diabetes 
who meet the following glucose -based parameters: HbA1c ≤7.0%, plus an  OGTT fasting plasma 
RISE Adult Medication  Protocol   Page 20 
 
 CONFIDENTIAL  glucose 95 -125 mg/dl and a [ADDRESS_386536] challenge glucose ≥140 mg/dl. Participants will be 
randomized to: (1) metfo rmin alone for 12 months, (2) 3 -months basal insulin glargine  titrated 
to normalize fasting glucose followed by 9 months metformin , (3) liraglutide plus metformin for 
12 months , or (4) placebo  for 12  months . Volunteers will be recruited  over a three -year period 
and follow ed for a total of 21 months following randomization. After baseline assessments and 
the run -in period, participants will be treated with active medication or placebo for 12 months. 
To determine if treatment has persistent benefits on ß-cell function, subjects will be followed 
after discontinuation of treatment for a minimum of 3 months and up to 9 months  if possible . 
Primary and secondary assessments will be performed at various time i ntervals while 
participants are receiving therapy and after medication discontinuation. The timing of the 
study, including interventions and testing, is shown in Figure 1.  
 
Figure 1 : Timing of interventions and outcomes testing for RISE Adult Medication Protocol  
The chosen interventions are intended to test whether “resting” the ß -cell (metformin alone or 
metformin following normalization of fasting glucose with  long -acting  insulin) or “improving” ß - 
and -cell function (liraglutide) will retard the natural progression of prediabetes and type [ADDRESS_386537] is seen after 12 months of treatment, then it is very unlikely that a shorter 
treatment period would be efficacious. Complete  end-of-study measures will be performed at 
the end of the 3 -month washout period (15 months on study)  and used for the primary analysis 
of the study . Where possible , ß-cell function will be measured using an OGTT at [ADDRESS_386538] 
therapy (21 months on stu dy) to evaluate whether treatment effects persist beyond the initial 

RISE Adult Medication  Protocol   Page 21 
 
 CONFIDENTIAL  3-month washout period. Full evaluation of the length of any durable response beyond these 
time points will require future studies designed specifically to address that question.  
3.2 Primary Outcomes  
The primary objective of the RISE Study  is to evaluate the effects of randomized treatment on 
ß-cell function, measured by [CONTACT_300121]. Given that insulin and C -peptide 
are both used in quantifying ß -cell function, each of them will be measured in certain or all tests 
in part to avoid the problem of collinearity when performing the statistical analyses.  
Two co -primary outcomes  are specifie d:  
 ß-cell function measured as the second phase response (steady -state of the 
hyperglycemic clamp ) (100 -120 minutes of glucose infusion)  [64]. This will be calculated 
as mean C-peptide at steady state,  adjusted  for insulin sensitivity using the 
hyperglycemic clamp -derived measure of insulin sensitivity (gluco se disposal 
rate/insulin: GDR/I) . 
 ß-cell function measured as AIRmax ( arginine -induced acute insulin response at 
hyperglycemic glucose ; ß-cell secretory capacity ) [30]. This will be calculated as the 
incremental area under the C-peptide curve from [ADDRESS_386539] asma glucose ≥450 mg/dl, adjusted for insulin sensitivity measured by 
[CONTACT_300122] . 
Overall, for primary and secondary outcomes  we will use the insulin sensitivity measured during 
steady state of the hyperglycemic clamp ( glucose disposal rate [d erived from the stea dy state 
glucose infusion rate] divided by  [CONTACT_313987] 100 -120 min) for 
adjustme nt of ß -cell function measures [69]. 
The mai n analysis will evaluate the effect of study treatments to induce durable improvement 
in these primary outcome measures of ß -cell function, by [CONTACT_313988] a 3 -month medication washout . The study will be analyzed under  the 
intention -to-treat principle . 
3.3 Secondary Outcomes  
There are  a number of pre -specified secondary outcomes . These include measures derived 
from the hyperglycemic clamp that are not specified as primary outcomes ; measures derived 
from the OGTT; analyses related to treatment effect at the end of the 12 month active 
intervention period compared to pre -treatment baseline; and analyses related to various 
putative predictors of treatment outcome.  
RISE Adult Medication  Protocol   Page 22 
 
 CONFIDENTIAL  As presented in  Figure 1, the timing of available secondary measures differs according to 
measurement methodology. Secondary outcomes  will be evaluated by [CONTACT_7586] -to-treat 
analyses when evaluating effects of randomized study treatments.  
3.3.1 ß-cell Function and Glucose Tolerance  
(i) Hyperglycemic clamp -derived ß-cell measures :  
a. First phase insulin response (incremental insulin area from 0 -10 minutes after initial 
glucose bolus)  
b. First phase C -peptide response (incremental C -peptide area from 0 -10 minutes after 
initial glucose bolus)  
c. Disposition index derived from a and b, adjusting for insulin sensitivity using the 
hyperglycemic clamp -derived measure of insulin sensitivity (glucose disposal 
rate/insulin: GDR/I)  
d. Second phase insulin response, with adjustment for insulin sensitivity using non -
clamp -derived surrogate measures  
e. AIRmax response to arginine calculated using insulin concentrations and adjusted for 
insulin sensitivity  
(ii) OGTT -derived ß-cell measures :  
a. Early insulin response to oral glucose (insulinogenic index: ∆ insulin from 0 -30 
minutes/∆ glucose from 0 -30 minutes [∆I/∆G])  
b. Early C -peptide response to oral glucose (parallel to (a))  
c. Oral disposition index (DIo; insulinogenic  index adjusted for insulin sensitivity)  
d. Modeled parameters of ß-cell function (ß -cell glucose sensitivity, rate sensitivity and 
potentiation factor; static, dynamic, and total ß -cell glucose sensitivity)  
e. Ratios of incremental insulin/glucose (iAUCins/iAUC g) and C -peptide/glucose (iAUCc -
p/iAUCg) responses from 0 -120 minutes  
f. Incremental glucose (iAUCg) response as a measure of glucose tolerance  
g. 2-hour glucose  
h. GLP-1 total and incremental response to oral glucose load (samples will be collected, 
and measured  for this analysis if funding allows)  
(iii) Fasting measures :  
a. Glucose  
b. Proinsulin/insulin ratio  
c. HOMA %B (using the Oxford calculator)  
d. HbA1c  
RISE Adult Medication  Protocol   Page 23 
 
 CONFIDENTIAL  3.3.2  -cell Function  (contingent on funding)  
A. Hyperglycemic clamp -derived measures :  
a. Glucagon suppression in response to sustained hyperglycemia during the clamp (the 
decrement in glucagon concentration from baseline to nadir value  at 100 -120 
minutes ) 
b. Acute g lucagon response  to arginine (the increment al increase in glucagon 
concentration from pre -arginine baseline for the 10  minutes after the arginine 
injection ) 
B. OGTT -derived measures : integrated glucagon response from 0 -120 minutes  
C. Fasting measures : glucagon  
3.3.3  Insulin Sensitivity  
(i) Hyperglycemic clamp -derived measures : glucose disposal rate at steady state (100 -120 
minutes) divi ded by [CONTACT_313989]  
(ii) OGTT -derived measures :  
a. Matsuda index  
b. Model -derived insulin sensitivity  
(iii) Fasting measures :  
a. 1/fasting insulin,  
b. HOMA -S (using the Oxford calculator),  
c. QUICKI  
3.3.4  Blood and Urine Biomarkers  
(i) Glycemic control : HbA1c ( baseline predictor, and as a time -dependent treatment       
outcome)  
(ii) Adipokines/inflammatory markers : adiponectin; others contingent on funding (see list 
above in Section 2.8.1)  
(iii) Non -esterified fatty acids  
(iv) Renal/vascular : urinary albumin/creatinine ratio at baseline (contingent on funding)  
3.3.5 Physical  Measures  
(i) Physical measures : blood pressure, body weight, body mass index, waist  and hip  
circumference  
RISE Adult Medication  Protocol   Page 24 
 
 CONFIDENTIAL  3.4 Treatments  
3.4.1 Three -week Placebo Run -in Phase  
Prior to randomization, eligible volunteers will participate in a 3-week run -in period. They  will 
be instructed by [CONTACT_313990]. At the end of the placebo -run in period, they will return an y 
unused medication which will be counted  to assess adherence . Participants  taking <80% of the 
medication will be excluded from further participation.  
Those who have been  compliant with medication use ( ≥80%) will be eligible to participate and 
will undergo the baseline study procedures. On ce these are completed, and if willing to 
undergo these tests repeatedly as required by  [CONTACT_1758], they will be randomized to one of the 
treatment arms and will enter  the active treatment phase. In addition, after completing the first 
set of study procedur es, they will receive instruction in lifestyle modification , including 
individualized instruction on weight loss, exercise and diet.  
3.4.[ADDRESS_386540] been 
assigned to metformin or placebo. Double blinding of these two groups will be done to 
minimize dropout of th ose participants assigned to placebo.  
The two groups receiving injectables (i.e., liraglutide and insulin glargine) will not be masked to 
the intervention.  
All medications used in RISE are approve d for treating type 2 diabetes and will be used 
according to  the label; Investigational New Drug  (IND) application s will be obtained for use of 
all medications in individuals with prediabetes . For study procedures performed during the 
active phase of treatment, study medications will be withheld on the morning of t esting . 
3.4.[ADDRESS_386541] 
tolerated the 0.6 mg daily dose. Likewise, after one week at 1.2 mg daily, the dose will be 
increased to 1.8 mg daily, the maximal recommended daily dose  in the treatment of diabetes . If 
participants cannot to lerate the higher dose, they will revert back to the previously tolerated 
dose and will remain on that maximal tolerated daily dose for the  duration of the study . Once 
the maximal dose of liraglutide has been reached and is tolerated, metformin will be ini tiated 
and titrated as described above . If the combination of the medications produces intolerable 
adverse effects, liraglutide treatment will be retained in preference to metformin.  
3.4.5 Insulin Glargine Followed by M etformin  
Insulin will be titrated over a pe riod of one month based on self blood glucose monitoring to 
achieve a fasting blood glucose of 80 -90 mg/dl without hypoglycemia, and then continued with 
dose adjustment to maintain the fasting glucose in this range. Insulin glargine has been shown 
to be ti tratable in individuals with prediabetes and established diabetes to achieve fasting 
glucose concentrations of <95 mg/dl  without a marked increase in recurrent or severe 
hypoglycemia  [44]. Following [ADDRESS_386542] -treatment Follow U p  
Following the completion of the intensive re -assessments  (hyp erglycemic clamp and OGTT)  
after [ADDRESS_386543] 3 
months off treatment (i.e., 15 months after randomization), the hyperglycemic clamp and OGTT  
will be repeated to determine the durability of the effects of the active interventions o n ß- and 
RISE Adult Medication  Protocol   Page 26 
 
 CONFIDENTIAL  -cell functi on. Although it is unlikely in this study population, participants may experience 
deterioration in ß -cell function during this 3 -month wash out period, and require rescue 
therapy. Criteria for rescue, and protocol -specified rescue therapy, are described be low (see 
Section 7.4). Participants  who do not require rescue  will undergo the final clamp and OGTT 
procedures at the end of the 3 -month wash out period. They will then continue to remain off 
study medications and retesting will occur  9-month s following discontinuation of the 
intervention (i.e., 21 months after randomization). The rescue protocol will be utilized, as 
needed, during this last 6 -month follow -up period. Following the complete 9 -month washout 
period, patients will be referred to their primary  care provider for further follow up.  
3.4.8 Rescue  
The approach to rescuing a participant with severe hyperglycemia is described in Section 7.4. 
3.5 Inclusion Criteria  
1. Fasting plasma glucose 95 -125 mg/dl plus 2-hour glucose ≥140 mg/dl on 75  gm OGTT 
plus HbA1c  ≤7.0%. There is no upper limit for the 2 -hour glucose on OGTT.  
2. Age 20 -65 years  
3. Body mass index ( BMI) ≥25 kg/m2 (≥23  kg/m2 in Asian Americans) but ≤ 50 kg/m2 
4. Self-report ed diabetes <1 year in duration  
5. Drug naïve ( no prior to oral glucose lowering agent(s), insulin  or other injectable 
glucose lowering agents)  
3.6 Exclusion criteria  
1. Underlying disease likely to limit life span and/or increase risk of intervention  or an 
underlying condition that is likely to limit ability to participate in outcomes assessment  
2. An u nderlying disease that affects glucose metabolism other than type [ADDRESS_386544] glucose metabolism, or has an underlying condition that 
is likely to require such medications  
4. Active infections  
5. Renal disease  (eGFR <45 mL/minute/1. 73 m ) 
6. Anemia (hemoglobin <11 g/dl in women, <12 g/dl in men) or known coagulopathy  
RISE Adult Medication  Protocol   Page [ADDRESS_386545] be able 
to safely tolerate administration of int ravenous fluid s required  during clamp studies.  
8. History of conditions that may be precipi[INVESTIGATOR_313957] a study drug:  
a. Pancreatitis  
b. Serum ALT more than 3 times the upper limit of normal  
c. Excessive alcohol intake  
d. Suboptimally treated thyroid disease  
e. Medullary carcinoma of the thyroid or MEN -2 (in  participant or a family history)  
f. Hypertriglyceridemia (>400 mg/dl despi[INVESTIGATOR_2391])  
9. Conditions or behaviors likely to a ffect the conduct of the RISE  Study  
a. Unable or unw illing to give informed consent  
b. Unable to adequatel y communicate with clinic staff  
c. Another household member is a part icipant or staff member in RISE  
d. Current , recent  or anticipated participation in another intervention research 
project that would interfere with any of the  interventions/outcomes in RISE  
e. Weight loss of >5% in past three  mon ths for any reason other than post -partum 
weight loss.  Participants taking weight loss drugs or using preparations taken for 
intended weight loss are excluded.  
f. Likely to move away from participating clinics in next  two years  
g. Women of childbearing potential  who are unwilling to use adequate 
contraception  
h. Current (or anticipated) pregnancy and lactation.  
i. Major psychiatric disorder that, in the opi[INVESTIGATOR_300098], would impede the 
conduct of RISE  
10. Additional conditions may serve as criteria for exclusion a t the discretion of the local 
site.  
Further details pertaining to exclusion criteria are specified in the Manual of Procedures.  
RISE Adult Medication  Protocol   Page [ADDRESS_386546] to anticipated differences in the participant 
populations. For each clinical center, the Coordinating Center  (CoC) will generate  two 
randomization scheme s using a permuted  block design . In this way, s ample sizes across the four 
treatment arms will remain relatively equivalent as the trial progresses . The clinical center staff 
will use  a computer -based system to input eligibility data and receive a random treatment 
assignment.  
3.[ADDRESS_386547] saline to assess 
compliance with possible study medications. After randomization, the metformin and placebo 
medications will be masked through a metformin -matched placebo. The insulin followed by 
[CONTACT_313991] e plus metformin arms will be unmasked.  
Because the primary outcomes are based on a single set of measurements taken 3 -months 
following medication withdrawal, the outcome measurements are inherently masked  to both 
participants and investigators . Participants and clinical center staff will be masked to study 
results until after the final outcome measurements are complete.  
4 RECRUITMENT  
4.1 Recruitment   
The primary sourc e of participants for the RISE S tudy is the active patient population of the 
study si tes and their usual referral sources. Participants will be recruited over a three year 
period. Recruitment techniques include notices placed on bulletin boards at the medical 
centers, newspaper and radio advertisements and public service announcements, and  referral 
from colleagues. Prescreening of electronic and clinical medical records is strongly encouraged 
to reduce available screen failure rates. Selection is based solely on the participant's ability to 
meet the criteria stated in the protocol and his/h er willingness to participate in the study. Site -
specific recruitment strategies are developed by [CONTACT_313992].  
The performance of the clinical centers in recruiting and retaining eligible RISE participants will 
be monitored by [CONTACT_313993]. Monthly recruitment 
summaries will be issued throughout the recruitment and randomization period detailing the 
number of potential participants screened, number randomized, and reasons for ineligibility or 
of refusal to pa rticipate by [CONTACT_138554]. The reasons for ineligibility or refusal to participate 
RISE Adult Medication  Protocol   Page 29 
 
 CONFIDENTIAL  will be compared among the clinical centers, and if large differences are found, explanations for 
these differences will be sought. If the randomization rate falls below the desired number of 
participants per month, data on reasons for ineligibility and refusal will be used to try to 
identify strategies that would increase the randomization rate. Site visits may be needed and 
assistance will be offered to clinical centers struggling with recruitment efforts.  
4.2 Description/Justification of the Target Study P opulation  
Preliminary screening will be done to enrich the yield of i ndividuals who have prediabetes or 
type 2 diabetes . These individuals will be invited for initial field  testing using HbA1c criteria. This 
testing will be performed on i ndividuals who are highly predisposed to  develop type 2 diabetes 
including , but not limited to, those with  one or more of the following features : 
 Known i mpaired glucose tolerance (IGT) and/o r impaired fasting glucose (IFG)  
 Overweight or obesity  (BMI ≥25 kg/m2 (≥23 kg/m2 in Asian Americans) but ≤ 50 kg/m2) 
 Age >45 years  
 First degree relative with type 2 diabetes  
 Sedentary lifestyle  
 Those with low HDL cholesterol or high triglycerides, hypertension ( i.e., “the metabolic 
syndrome”)  
 Certain racial and ethnic groups (e.g., Non -Hispanic Blacks, Hispanic/Latino Americans, 
Asian Americans and Pacific Islanders, and American Indians and Alaska Natives)  
 Women who had gestational diabetes, or who  have had a baby [CONTACT_17832] 9 pounds or 
more at birth  
 Women with polycystic ovary syndrome (PCOS)  
 
The lifetime risk for type 2 diabetes among these groups is substantially higher than that seen 
in the general population . Further,  the presence of more than o ne of these factors enhances 
the likelihood of development of type 2 diabetes to an even greater degree than does the 
presence of any single factor noted above . A recent evaluation of diabetes risk attempted to 
quantify the value of well known diabetes -associated risk factors [88]. 
The presence of  risk factors/characteristics noted above will prompt screening these persons 
with a POC  HbA1C; those who have a value of ≤7.2% will be asked to undergo a standard [ADDRESS_386548], the proportion of subjects who will 
undergo  an OGTT will be at high likelihood of having IGT or newly diagnosed type 2 diabetes by 
[CONTACT_313994]1C. This approach is designed to increase the 
RISE Adult Medication  Protocol   Page 30 
 
 CONFIDENTIAL  yield of detecting IGT and type 2 diabetes while simultaneously maximizing the use of resources 
(both in terms of effort of personnel and use of testing supplies).  
This strategy will yield individuals who will be identified as being at high risk for ß -cell 
dysfunction (risk group plus POC  HbA1C ≤7.2% ). Of those who undergo a [ADDRESS_386549] a fasting plasma glucose 95 -125 mg/dl plus a 2-hour glucose 
≥140 mg/dl  plus a laboratory -based HbA1c ≤ 7.0%. There is no upper limit for the [ADDRESS_386550] will be  provided adequate time to read and understand the 
written consent and ask questions as necessary . If they choose, they may take a dditional time 
to discuss the study with family and/or physicians outside the clinic setting . Consent documents  
are not signed  until volunteers  demonstrate adequate understanding of all aspects of the study 
and consent process . A copy of the consent will b e given to the subject . There will be two 
consent forms – one for the Screening stage and one for the Intervention stage. Model consent 
forms are provided in Appendix A.  Written informed consent will be obtained prior to initiation 
of any study -related act ivities.  
In the event that a significant protocol change occurs, the informed consent documents will  be 
adjusted appropriately and sites will submit the revised documents to their Institutional Review 
Board (IRB) for approval. Local IRBs will determine whe ther it is necessary to re -consent 
participants . 
Sites  will submit to the CoC stamped IRB approval letters and current copi[INVESTIGATOR_313958], and annually thereafter . These records will be maintained by [CONTACT_313995] a central archive .  
4.[ADDRESS_386551] 
demanding procedures. Once a participant is determined to be ineligible, the screening  process 
stops.  
RISE Adult Medication  Protocol   Page 31 
 
 CONFIDENTIAL  The staged screening process  is intended to accomplish the following:  
 identify potentially eligible participants  for RISE ,  
 verify eligibility of participants ,  
 accomplish the objectives of the informed consent process,  
 complete a run -in period,  
 establish a research cohort likely to complete the study and adhere to the medication 
schedule and the complex testing of ß -cell function and related measures , and  
 randomize participants into RISE.  
Complete definitions and proced ures are in the Manual of Procedures.  
All steps below will be conducted if and only if the individual provides written informed consent 
for participation in RISE. If for any reason the participant wishes not to participate in any of the 
activities and expe rimental procedures outlined in the informed consent, the consent form will 
not be signed and no further data collection  or biological testing will be conducted. If the 
participant agrees to participate in RISE, he/she will provide written documentation by [CONTACT_313996]. If for any reason the participant wishes to withdraw from the study at any 
time, there will be no pressure upon the participant to continue and withdrawal  will be 
documented.   
Staged screening and enrollment includes the following steps:  
1. Initial Contact : [CONTACT_313997] 2 diabetes by [CONTACT_313998] (Section 4 .2). Potent ial 
participants are seen and given detailed information about RISE, including research 
interventions, randomization, masking, test procedures, risks and benefits, and the 
eligibility process. If they give oral and/or written consent, they are first interv iewed and 
records are reviewed for personal and medical history. If they pass these completely 
noninvasive eligibility criteria, they will have a POC HbA1c measurement. Should their 
value be ≤7.2%, they will be invited to attend the clinic for a full scree ning visit where a 
complete history will be taken and lab tests performed.  
2. Screening : If the participant meets initial inclusion criteria, he/she will return for a 
physical examination, full eligibility testing, and instruction in taking medication for the  
placebo run -in phase. A fasting [ADDRESS_386552] be between 95 -125 mg/dl and  the [ADDRESS_386553] be ≥140 mg/dl  and the laboratory -based HbA1c must be≤ 7.0%. 
3. Run-in: If the above criteria are met, the participant will be asked to undergo a 3 -week 
run-in period. T he run -in period (described in Section 3 .4.1) allows staff to evaluate a 
patient’s suitability for RISE. At the end of the run -in, clinic staff will assess the  patient’s 
RISE Adult Medication  Protocol   Page 32 
 
 CONFIDENTIAL  adherence to medication taking, assess final eligibility criteria, and determine whether 
the patient should be randomized to RISE.  
4. Final screening visit and randomization:  If the participant is eligible , informed consent is 
obtained , baseline data are collected and the OGTT and hyperglycemic clamp are 
performed. If after completion of these studies the participant is willing  to be 
randomized, the participant is randomly assigned to a treatment group.  
If during the screening process t he participant is deemed ineligible, but his/her condition 
changes during the recruitment period (e.g., the participant has uncontrolled hypertension that 
becomes adequately treated  or an active infection that has resolved ), he/she may be 
reconsidered for inclusion if he/she maintains eligibility for three months. Screening procedures 
are re -initiated and the participant must meet all eligibility criteria at the time of re -enrollment.  
A minimal amount of data is recorded on participants who fail screening (such as age group, 
gender, race/ethnicity, diabetes duration) for purposes of comparing participants versus 
nonparticipants.  
5 PATIENT MANAGEMENT   
5.1  Description of RISE Research Facility T reatment(s)  
Study treatment interventions are described in detail abov e (Section 3.4 ). Glucose management 
(including study medications) will be provided free of charge to RISE participants. In accordance 
with standards of care, HbA1c will be monitored every [ADDRESS_386554] of 
prediabetes and diabetes care, the research study will not assume responsibility for the medical 
care of the participant. Non -glucose aspects of diabetes care (e.g., blood pressure, lipi[INVESTIGATOR_805] , 
obstructive sleep apnea) and non -diabetes related medical problems will be referred to the 
participant’s primary care provider. When a potential treatment could affect the study’s 
outcome(s), the RISE physician may discuss the choices with the participan t’s primary care 
provider. RISE Study labs will be shared with the provider, with the participant’s permission. For 
those participants who do not have a primary care provider, the study staff will help find 
appropriate medical care.  
5.2  Drug Distribution  
Stud y medications will be distributed directly to individual study centers. Individual centers will 
organize and maintain inventory, in cooperation with their investigational or research 
pharmacy. Sites will  ensure that sufficient medication is always on  hand to allow medication 
RISE Adult Medication  Protocol   Page 33 
 
 CONFIDENTIAL  distribution for the next three month period. This includes medications required for the next 12 
randomized enrollees (i.e. , on average three initial distributions for each of the four  treatment 
arms) plus all of the upcoming distributi ons to enrolled participants who will be returning 
within three  months. Expi[INVESTIGATOR_313959].  
Except for the placebos (metformin and liraglutide) distributed during the 3 -week run -in period , 
medication will be dispensed to participants in 3 -month quantities, and 
bottles/boxes/containers will be collected from participants at the quarterly visits to allow 
compliance assessment by [CONTACT_21173][INVESTIGATOR_313960]. 
Subsequent treatment supplies will be provided with each quarterly visit.  
Non-study medications will not be provided through the RISE study clinical centers.  
5.3  Adherence M easures  
Adherence will be  documented, monitored, and addressed as part of participant care and 
management and to monitor whether procedures are being implemented and followed 
equivalently across all sites . Adherence refers to all study procedures – not only taking the 
prescribed a mount of study drug, but also attending scheduled study visits and completing 
procedures at those visits . The goal is to maintain high levels of adherence in all participants 
and across all sites. Primary adherence measures will address visit attendance an d completion 
of study procedures, medication adherence, and adherence to recommended home glucose 
monitoring . Medication adherence will be assessed on a quarterly basis, by [CONTACT_21173][INVESTIGATOR_313961].  Participants will be instructed to 
bring all study medications (including empty bottles/vials/pens) to study visits.  
5.3.[ADDRESS_386555] will be used to assess 
compliance, and confirmed with a residual volume assessment as with liraglutide pens.  
5.3.4 Metformin/Placebo  
Active or placebo metformin compliance will be assessed by [CONTACT_313999] .  
5.[ADDRESS_386556] predicted withdrawal rates of 10% during the 
15-months of primary data collection  and have adjusted sample size to meet study 
requirements. However, lower rates of attrition are desirable .  
The Study Coordinator at each site is primarily responsible for monitoring participant attrition 
and initiating team conferences for  retention strategies or dropout recovery rates. Individual 
sites will develop strategies to enhance retention specific to their locale and specific 
population . Activities at both the national and local level will be  coordinated to maximize 
retention and m inimize attrition . Subjects missing scheduled visits will be contact[CONTACT_11252] [ADDRESS_386557], the site will send a certified letter to  the participant to 
encourage continuation in the trial even if they no longer wish to take the study medication. At 
the local level, study staff will implement efforts to personalize the study (mailing out personal 
notes, birthday cards, etc .). 
Attrition is monitored regularly by [CONTACT_314000] . An 
attempt is made to collect data on the reason for leaving the study in the case of a participant 
who withdraws . Assistance is offered to any site with a higher than  average attrition rate . Sites 
will also be encouraged to share their ideas and experiences via regular communication and 
conference calls for Study Coordinators. The CoC will prepare monthly reports on visit 
completion, compliance with the RISE Study prot ocol and participants on inactive follow -up.  
RISE Adult Medication  Protocol   Page 35 
 
 CONFIDENTIAL  6 DATA COLLECTION  
6.1  Main Study Procedures  
The timing of major study procedures during the different phases of the study is illustrated in 
Figure 1. Outcomes using hyperglycemic clamp procedures will be obtained a t baseline, at the 
end of 12 months of treatment, and after a 3 -month washout period (i.e. , [ADDRESS_386558] 
randomization) . Additional  outcomes will be obtained from the OGTT  concurrent with the 
hyperglycemic clamp procedures, and also at additional time po ints -- at 6 months on therapy, 
and at 9 months after stoppi[INVESTIGATOR_7374] (i.e. , [ADDRESS_386559] randomization). Blood and urine 
samples for planned measures will be collected at these visits, along with extra blood and urine 
samples that will be stored for fu ture analyses. Further details on these measures are provided 
below , and are summarized in Figure 1 above. All procedures and measures will be conducted 
by [CONTACT_314001].  
6.1.1 Fasting Blood and Urine Samples  
HbA1c will be measured and fasting blood and urine samples will be collected at each 3 -
monthly study visit. Aliquots of  fasting  blood  and urine will be stored for subsequent 
measurement of biomarkers. A blood sample for DNA will be collected at randomization  for 
subsequent genetic a nalysis should funding become available . Routine chemistries for safety  
(examples include complete blood count, liver function tests, pregnancy tests) will be done at 
screening  and at six  months.  
6.1.[ADDRESS_386560] ( OGTT ) 
Participants will come to the clinical research testing facility in the morning following a [ADDRESS_386561]. They will drink  75 gram s of an oral glucose solution  (centrally provided 
from a single manufacturer) over ≤5 minutes. Blood samples will be obtained 10, 20, 30,  60, 90, 
120, 150 and 180 min after the  glucose ingestion. OGTT procedures will be performed at 
baseline, at 6 and 12 months on active treatment, and 3 and 9 months  after stoppi[INVESTIGATOR_206816] , i.e. , 15 and 21 months after randomization . 
6.1.3  Hyperglycemic Clamp  
Hyperglycemic clamps ( goal steady state glucose levels of 200 mg/dl  and >450 mg/dl ) will be 
performed at baseline , [ADDRESS_386562] randomization (i.e.,  after 3 months of washout ). Participants will  return to the 
testing facility  to undergo the clamp  after a [ADDRESS_386563].  The clamp will be 
performed on a day separate from the OGTT.  
RISE Adult Medication  Protocol   Page 36 
 
 CONFIDENTIAL  The clamp procedure will incorporate 3 main sets of blood sampling for the planned outcome 
measures: first phase (0 -10 minutes); second phase (100 -120 minutes); and maximal stimulated 
responses (from 10 minutes before arginine until 10 minutes after argini ne). To guide the 
clamp, a small volume of arterialized venous blood will be obtained at 5 -min intervals 
throughout for clamp for measurement of plasma glucose concentration  and titration of the 
dextrose infusion . 
For the OGTT and clamp measures, participa nts will be asked to refrain from vigorous exercise 
and tobacco use for 24 h ours  before the baseline measures . Study m edications will be withheld 
the morning of testing . 
6.2  Eligibility Screening Measurements  
Screening and run -in pr ocedures are listed in Tabl e 1. 
Prescreening (initial contact) :  Prescreening for potential eligibility will be done using a single 
random capi[INVESTIGATOR_1396] (fingerstick) blood sample for measurement of HbA1C with a POC  instrument . 
Participant s are eligible to continue screening procedures if the POC HbA1C is ≤7.2%% and 
screening questionnaire that includes a focused medical history, anthropometric  and blood 
pressure measures indicate that they meet initial eligibility criteria . Subjects who are discovered 
to have HbA1c >7. 2% will be exclude d from participation and referred for formal diabetes 
assessment and treatment through their regular health care provider(s).   
Screening : Participants  who meet pre -screening eligibility criteria will present to the study 
center for formal screening to undergo a standard [ADDRESS_386564] -load samples will be obtained 
(a laboratory -based HbA1c must be ≤ 7.0%, fasting glucose must be 95 -125 mg/d l and [ADDRESS_386565] be 140 mg/d l for eligibility in RISE ). Eligibility lab tests will also be performed, 
including electrolytes, TSH†(when clinically indicated) , triglycerides, cr eatinine, ALT, 
hemoglobin , and pregnancy test.  
Placebo run -in: Participants  meeting eligibility criteria will be instructed to begin the 3-week 
placebo run -in. Participants  who have <80% adherence  with study medications during this run -
in phase will be withdrawn from the study and no further study procedures will be performed. 
Participants  who are adherent with ≥80% of study medication during run -in will proceed to 
baseline study measurements . Participants will be asked demographic and medical hi story 
information.  
RISE Adult Medication  Protocol   Page 37 
 
 CONFIDENTIAL  Table 1: Data Collection During Screening and Run -In Procedures  
STEP  TEST / PROCEDURE  COMMENTS  
1) Pre-screening  Screening HbA1C (POC)  Continue screening if ≤7.2%  
Screening questionnaire  Initial review of eligibility  
Height, weight and BP  Initial screening for eligibility  
2)  Screening  HbA1c, 75 g ram OGTT (central lab); 
glucose at 0 and 120 min  Eligibility  HbA1c ≤7.0%,  fasting 
glucose 95 -125 mg/dl; 2 -h 
glucose 140 mg/d l 
Eligibility labs *  Laboratory eligibility criteria  
Demographics, m edical history , 
medications and physical 
examination  Eligibility evaluation  
3) Run-in  Placebo dispensed  Initiate run -in 
Evaluate  Determine eligibility for 
randomization  
*Eligibility labs: electrolytes, TSH†, triglycerides , creatinine , ALT, hemoglobin   
†TSH should be assessed as part of trial screening procedures in the following settings: 1) reported use of anti -
thyroid medication, 2) reported use of thyroid hormone, 3) reported history of thyroid disease or 4) clinical 
suspi[INVESTIGATOR_1884] t hyroid disease on history and physical.  
 
6.[ADDRESS_386566] -Randomization Measures  
Measurements to evaluate safety, adherence, and outc omes are summarized in Table 2. The 
outcomes , derived from hyperglycemic clamp procedures, will be measured at baseline, 12 
months (end of treatment ), and [ADDRESS_386567] randomization  (end of washout).  OGTT 
outcomes  measurements and blood sampling for other outcomes  will be performed at 
baseline, 6 and 12 months following randomization (on treatment) and then at 15  and 21 
months (off treatment). Hyperglycemic clamp and OGTT outcomes measures are described in 
detail above. Other measurements are discussed below.  
Table 2:  Timeline of Outcomes, Safety Testing, and Adherence Measures  
 Baseline/
Pre 
random -
ization  Post Randomization  
Month  
  3  6  9  12  15  18  21  
Physical          
Height  x        
RISE Adult Medication  Protocol   Page 38 
 
 CONFIDENTIAL   Baseline/
Pre 
random -
ization  Post Randomization  
Month  
  [ADDRESS_386568] / Hip circumference  x    x x  x 
Blood pressure  x x x x x x x x 
Outcomes          
Hyperglycemic clamp & AIR max x    x x   
OGTT  x  x  x x  x 
HbA1C x x x x x x x x 
Questionnaires  x        
Sleep  
(Pi[INVESTIGATOR_313962], Epworth 
Sleepi[INVESTIGATOR_7110], Berlin 
Questionnaire)  x        
Biomarkers  x  x  x x  x 
Stored Specimens          
DNA  x        
Plasma / Serum  x  x  x x  x 
Urine  x  x  x x  x 
Safety          
SMBG for those on insulin  x x       
Hemoglobin or Hematocrit  x  x  x    
Blood chemistries**  x  x      
Adverse events  x x x x x x x x 
Pregnancy test (local measure)  x x x x x x x x 
Medication adherence  x x x x x    
** fasting serum ALT and creatinin e; pr egnancy tests as needed based on symptoms and 
menstrual history  
6.3.[ADDRESS_386569] rib (waist), and at the top of the femur (hip) with the participant 
standing upright.  
RISE Adult Medication  Protocol   Page [ADDRESS_386570] 3 
months of the intervention (baseline to 3 months). During the insulin treatment phase , 
participants will record fasting blood glucose once daily, in the morning, to guide dose 
adjustment for the insulin. Routine chemistries c onsisting of hemoglobin or hematocrit  (local 
lab), serum liver enzymes (ALT) and creatinine will be collected for evaluation of liver and 
kidney function at screening and at six months  during treatment . Adverse events (AE) will be 
surveyed at each visit us ing a standardized questionnaire . Pregnancy tests (local lab) will be 
performed in women with child -bearing potential prior to study procedures at each v isit. 
6.3.4  Participant P rotocol Adherence  
Pi[INVESTIGATOR_313963] -in to the en d of the treatment period . 
Similarly, insulin or liraglutide pen residual volume will be determined. Participants will be 
asked to bring all medications  to all visits . Self -monitoring blood glucose (SMBG)  data will be 
reviewed at the [ADDRESS_386571] in keepi[INVESTIGATOR_313964].  
7 SAFETY / HUMAN SUBJECTS PROTECTION  
This trial will be conducted in compliance with the protocol and all applicable regulatory 
requirements. All part icipating clinical sites must have a Federal -wide Assurance with the Office 
for Human Research Protections. All sites will follow HIPAA regulations.  
Prior to study initiation, the protocol and the informed consent documents will be reviewe d 
and approved by  [CONTACT_314002]  (DSMB ). Any amendments to the protocol or consent materials must 
be approved by [CONTACT_314003].  
RISE Adult Medication  Protocol   Page [ADDRESS_386572] (DSMB )  
A DSMB  comprised  of appropriately qualified and conflict -free independent experts is 
appointed by [CONTACT_48953] ( NIDDK) and 
provides input to the Institute. Board members are chosen by [CONTACT_941] N IDDK without consultation 
with the study investigators. The purpose of the Board is to assure independent review  as to 
whether study participants are exposed to any unreasonable risk because of study 
participation, and to monitor study progress and integri ty. In addition to safety monitoring, the 
Board can review unblinded study data and make recommendations for early termination of 
studies for achieving an end point or for futility . Before any of the RISE studies  can begin, the 
DSMB, in addition to the local IRBs, must approve the protocol. Any subsequent major changes 
to the protocol must also be approved by [CONTACT_300137].  
Following each DSMB me eting, a summary of DSMB recommendations is provided to the IRB o f 
each participating clinical center and other institutional monitoring committees/boards as 
needed.  
7.[ADDRESS_386573] an individual’s participation in the study.  At any time during the study, participants will 
have the option to withdraw from participation without reperc ussion. In the event that a 
participant withdraws, study medication will no longer be provided but the arm to which the 
participant was randomized will remain blinded, as the analysis will be one of intention -to-
treat.  
7.2.2  Safety Review Plan and Monitoring  
A. Justification of Sample Size – See S ection 9.3. 
B. Stoppi[INVESTIGATOR_1869] – The DSMB may suggest terminating a study arm at any time for safety 
or efficacy reasons. Details of interim analysis plans and stoppi[INVESTIGATOR_300104] 9.4 and 9.5.   
RISE Adult Medication  Protocol   Page 41 
 
 CONFIDENTIAL  C. Safety Monitoring Committee and Safety Review Officer – The study will appoint an 
internal Safety Monitoring Committee (SMC) which will review AEs or other safety -
related problems sent to them from the field. The RISE SMC will review AEs in a blinded 
manner. An e xternal Safety Review Officer will evaluate any serious adverse events 
(SAE) where the SMC is not in agreement about whether the event is related to study 
drug as well as certain specified SAEs of concern (e.g., pancreatitis). The Safety Review 
Officer wil l not be blinded to study intervention.  
D. Safety Review Plan – The DSMB will meet at least twice yearly  either in person or by 
[CONTACT_314004] 7.1. 
7.2.[ADDRESS_386574] privacy – Participants are identified within the study only by [CONTACT_314005] . No confidential identifiers are used in any data collection.  
B. Database Protection – All files are stored in a locked cabinet at the clinical centers, and 
data are entered into a secure, password -protected website maintained by [CONTACT_314006]. The 
CoC holds no personal identifiers and stores the data on its enterprise server accessible 
only by [CONTACT_173414].  At the end of the study, all records will be kept in a secure locale 
for a perio d dictated by [CONTACT_314007], 
whichever is longest.  
C. Confide ntiality During AE Reporting – AEs and SAEs are recorded on data collection 
forms and reported to the CoC without personal identifiers. Identifi ers on accompanying 
documents (such as medical records) are removed before submission to the CoC and 
any subsequent transfer to the Safety Monitoring Committee and/or Safety Review 
Officer.  
7.3  Expected Side Effects  
The RISE Study  will use the following medications: metformin, insulin glargine and liraglutide.  
Metformin:  Known adverse effects associated with metformin are primarily gastrointestinal 
(diarrhea, nausea, vomiting, abdominal bloating, flatulence, anorexia), hematologic (reduced 
vitamin B12 levels and, rarely, megaloblastic anemia), and the rare possibility of lactic acidosis. 
The risk of lactic acidosis associated with metformin use will be minimized by (1) monitoring 
liver transaminases, (2) monitoring renal function, and (3) temporary discontinuation of 
metformin before radiologic studies involving the inject ion of contrast dye, surgical procedures 
requiring reduced fluid intake, and serious illness that might be associated with hypoxia, 
dehydration, or shock.  
RISE Adult Medication  Protocol   Page 42 
 
 CONFIDENTIAL  Insulin glargine: The side effects of insulin glargine include hypoglycemia and weight gain. The 
occurrence of hypoglycemia will lead to insulin dose adjustment at the discretion of the 
investigator. Participants will be counseled about the possibility of weight gain while on insulin 
therapy and given dietary counseling and resources. Participants on ins ulin will perform SMBG 
to minimize the risk of hypoglycemia.  
Liraglutide : The most common adverse effects associated with liraglutide are gastrointestinal 
and include nausea, vomiting, and diarrhea. An increased risk of pancreatitis has also been 
reported.  A history of previous pancreatitis is an exclusion criterion and an absolute 
contraindication to continuing liraglutide. In addition, increased levels of calcitonin, which are 
associated with medullary thyroid carcinoma,  a rare form of thyroid cancer, hav e been reported 
in some animal and human studies. A history of medullary thyroid cancer or a family history of 
MEN -2 is an exclusion criterion in RISE.  
7.4  Risk Management  
Glucose management (including study medications) will be provided free of charge to RIS E 
Study participants while participating in the study. Participants will receive training about the 
proper use of hypoglycemic medications as well as education about the symptoms, causes and 
response to epi[INVESTIGATOR_313965] - and hypoglycemia. Participants who  develop symptomatic hypo - 
or hyperglycemia, or experience any side effects of medications or study procedures will be 
instruc ted to call the clinical site. The following p rocedures  will be implemented  to minimize 
risk to participants:  
 Hyperglycemia:  Parti cipants will be  instructed regarding the signs and symptoms of 
hyperglycemia and are to call the clinic with any concerns. To minimize the risk of 
symptomatic hyperglycemia, the following procedures will  be followed:  
 If HbA1c >7% at any routine quarterly v isit, therapy will be  invigorated by [CONTACT_314008]/or visits to encourage optimal medication adherence and 
lifestyle choices. HbA1c will be  obtained at the next quarterly visit. If HbA1c remains 
>7% but <8%, frequent contact [CONTACT_314009].  
 If HbA1c >8.0% at any routine quarterly visit, therapy will be  invigorated and HbA1c will 
be repeated after 6 weeks. If it remains >8.0%, outcome assessment will be  scheduled in 
2 weeks  (i.e., regardless of time since randomization).   
 If at any time – either a routine visit or when a participant is brought in due to 
symptoms – the HbA1c >9%, the HbA1c will be  repeated within 2 weeks and, if 
confirmed, the participant will be  scheduled for immediate outcome measurement.  
RISE Adult Medication  Protocol   Page 43 
 
 CONFIDENTIAL   Metabolic decompe nsation:  In the unlikely event that a study subject develops 
metabolic decompensation, defined as hyperglycemia (plasma glucose >300 mg/dl) 
accompanied by [CONTACT_23297] (e.g., vomiting, dehydration, lethargy) and/or 
moderate or large urinary ketone s, the  participant will be evaluated to determine if 
temporary use of insulin therapy is required. Once insulin is started, the site will attempt 
to wean insulin within 4 weeks. If insulin cannot be weaned off within 4 weeks, the 
patient will be  censored a t that time.  
 If outcome measurements are performed prior to the scheduled time points of 12 or 15 
months, once completed the participant will be referred back to their primary care 
provider for further care.  
 Gastrointestinal (GI) symptoms  are a com mon occ urrence with metformin and liraglutide. 
However, these symptoms more commonly occur early in the course of treatment . All 
eligible participants will be  slowly titrated to  the maximal tolerated  doses of metformin or 
liraglutide, in order to minimize  gastroi ntestinal side effects . For metformin, the dose will 
be started at [ADDRESS_386575] 
dose (for example, 1000 mg bid to 1000 mg + 500 mg; 1000 mg + 500 mg to 500 mg bid; 
etc.) . If symptoms persist, metformin will be  reduced to the next ste p. If GI symptoms 
resolve, metformin will be  re-escalated by 500 mg per day each week until reaching the 
previously tolerated dose . The participant will continue on the maximum tolerated dose. A 
similar procedure will be followed for liraglutide, with the relevant doses being 0.6, 1.2 and 
1.8 mg daily.  
 Anemia  may be an adverse effect of metformin. It  is defined as a hematocrit <30.0%, a 
hemoglobin <10 gm/d l, a decline in hematocrit by 4% from study entry, or a decline in 
hemoglobin by 2 gm/d l from study ent ry. If anemia persists for more than six months 
despi[INVESTIGATOR_19143], consideration will be  given to discontinuing study medication .  
 Renal insufficiency  increases the risk of lactic acidosis associated with metformin.  To asses 
renal insufficiency, serum creatinine and estimated GFR (eGFR) will be calculated using the 
CKD-Epi [INVESTIGATOR_10908]  (ref . Ann Intern Med. 2009;150(9):604 -612.) at screening and after six 
months on therapy .  Participants must have an eGFR of 45 mL/minute/1.73 m2 or higher to 
be eligible.  Metformin will be discontinued if eGFR is below 30 mL/minute/1.73 m2 at the 
Month 6 visit. If eGFR ≥30 and <45 mL/minute/1.73 m2 then the RISE Safety Committee will 
review the case to assess the benefits and risks of continuing treatment , and make a 
RISE Adult Medication  Protocol   Page 44 
 
 CONFIDENTIAL  recommendation to the clinical center investigators about whether to continue the 
participant on metformin.  
 Mild hypoglycemia is common in subjects  with prediabetes or diabetes being treated with 
medications  to lower  glucose levels in to or near the normal range . Participants will be 
educated to recognize and treat mild hypoglycemic epi[INVESTIGATOR_313966]. Adjustments to study medication will be 
made when appropriate.  
 Severe  hypoglycemia  is defined by [CONTACT_314010], the need for a 
third party to resolve a hypoglycemic epi[INVESTIGATOR_1865], or loss of consciousness or seizure . Study 
medications will be  adjusted downward  as appropriate.  
 Metformin and its placebo are temporarily discontinued 24 hours before, during, and for 48 
hours after any of the following events  to reduce the risk of lactic acidosis : 1) procedure 
involving the injection of contrast dye; 2) surgery or other procedure requiring general 
anesthesia; 3)  any illness that could be associated with hypoxia, circulatory failure, or 
dehydration; 4) hospi[INVESTIGATOR_059] . Serum creatinine will be rechecked no sooner than 48 hours 
after the conclusion of the event and study medication recommenced if appropriate .  
 Othe r indications for temporary or permanent discontinuation of study medication include:  
 Pregnancy:   Study medications will be discontinued if a participant becomes pregnant. 
The participant will be referred to a high risk obstetrics clinic for further care.  Study 
medications will not be administered if a participant plans to become pregnant.  
 Lactation:   No study medication will be administered to women who are nursing a baby.  
 Lactic acidosis:   Any study participant  who experiences a bout of lactic acidosis will have 
metformin and metformin placebo permanently discontinued.  
 Dermatological problems:   Any study participant  who experiences severe dermatological 
problems, such as urticaria, bullous rashes, exfoliative dermatitis, Stevens -Johnson 
syndrome, thought to be related to study medication will have  study medication 
permanently discontinued.  
 Pancreatitis:  Any study participant  who  is diagnosed with  pancreatitis during the study 
will have liraglutide permanently discontinued . 
 Medullary thyroid carcinoma: Any study participant who is diagnosed with medullary 
thyroid carcinoma during the study will have liraglutide permanently discontinued.  
 Adverse effect s of the study procedures may occur very rarely and include:  
o Glucose injection and infusion :  Irritation of a  vein resulting in phlebitis can occur with 
administration of concentrated glucose solutions.  The risk will be decreased by 
[CONTACT_314011] 45 
 
 CONFIDENTIAL  minimizing the use of concentrated solutions and selecting large veins for infusion of 
solutions.  
o Arginine:   Overdosage, especially in children, can be fatal. To reduce this risk, the dose 
of arginine will be weight based ( 0.07 gm/kg  in children) with a maximum dose of 5 gm 
per dose in both adults and children.  
7.5 Potential Benefits  
There is potential benefit of participation by [CONTACT_314012] 2 
diabetes. Prediabetic  participants are at increased risk of developi[INVESTIGATOR_313967] ; treatment is also predicted to slow progression from prediabetes to type [ADDRESS_386576] a condition that is becoming more prevalent a nd carries with it the risk 
of additional complications, participation will also benefit the individual, the researchers and 
society through the gaining of new knowledge.  
7.6  HIPAA – Protection of Patient I nformation  
All data collected in the process of pre -screening, screening, and conducting the proposed 
research will be stored and maintained  locally and centrally  in compliance with HIPAA 
regulations. Access to study data will be secure with limited, password -protected access. Only 
study personnel who are IR B approved will have access to data collected as part of these 
studies . Data entered into the central database  will be stored at the CoC on a server that is 
maintained with the highest stringency of protection . Similarly, data entered into local 
databases will be stored at the clinical center on a server that is maintained with the highest 
stringency of protection .  
[ADDRESS_386577] of this trial.  In 2013 the FDA 
issued an IND exemption for the RISE  Study . Therefore, the study group and NIDDK are not required to 
report any study adverse events to the FDA . 
RISE Adult Medication  Protocol   Page 46 
 
 CONFIDENTIAL  8.1  Definition of Serious Adverse Events  
a. The event results in an inpatient hospi[INVESTIGATOR_059] (any overnight stay associated with an 
admission).  
b. The event resu lts in the prolongation of a hospi[INVESTIGATOR_4408].  
c. The event results in permanent or severe disability.  
d. The event results in death.  
e. A pregnancy results in a congenital anomaly.  
f. The event results from an overdose (either accidental or experimental) of the study 
medication.  
g. The event is life -threatening.  
h. Treatment is required to prevent a serious event.  
8.2  Non -serious Adverse Events  
Non -serious adverse events are all AEs which do not meet the above criteria for “serious”.  
8.[ADDRESS_386578] form that is completed by [CONTACT_314013] r egular study  visit 
following commencement of study -related activities. Targeted non -serious AEs (e.g., abdominal 
pain) are ascertained by [CONTACT_314014] . AEs also include any significantly abnormal laboratory result obtained on the 
patient between visits or at the time of the visit . 
The clinical center staff who learn of an SAE must data enter  the completed RISE Serious 
Adve rse Event Report prior to the close of the following business day.  Upon request, all SAEs 
will be reported within the prescribed period to the relevant pharmaceutical sponsors.  
All pregnancies occurring during the study must be  reported by [CONTACT_314015]. This reporting must occur prior to the close of the business day  that follows the clinical 
center becoming aware of the pregnancy. Further, the outcome of the pregnancy must be 
determined and reported by c linical center staff as soon as possible after the pregnancy is 
completed. All this information will be reported within the prescribed period to the relevant 
pharmaceutical sponsors.  
RISE Adult Medication  Protocol   Page 47 
 
 CONFIDENTIAL  8.4  Tracking Adverse Events  
 Serious Adverse Events: SAEs will be monitored b y the RISE Safety Monitoring Committee, 
which will remain blinded to treatment arm. The external DSMB will monitor SAEs by 
[CONTACT_2939]. It is important to note that all serious and unexpected AEs must be reported 
to the CoC, regardless of the drug -relate d assessment. For example, a patient struck by 
[CONTACT_300146] a report, even though this is not likely to be a drug related event.  
 Non-serious adverse events : Non -serious AEs are tabulated by [CONTACT_314016] . 
Summaries of the  AEs, tabulated by [CONTACT_6903], are provided to the Safety Monitoring 
Committee , which reviews this summary during one of its regularly scheduled meetings .  
 Safety Monitoring Committee : The Safety Monitoring Committee reviews AEs in a blinded 
fashion. The commi ttee considers whether changes in the protocol (monitoring, consent 
process, etc.) are indicated based on the occurre nce, frequency, or severity of AEs. The 
committee also evaluates whet her there is any clustering of AEs by [CONTACT_6903] . Any concerns on 
the part  of the Safety Monitoring Committee  may be referred to the  Safety Review Officer 
and/or  DSMB, which can review SAEs in an unmasked manner.  
 Safety Review Officer : The Safety Review Officer will review any SAEs where the SMC is not 
in agreement about whether  the event is related to study drug, as well as certain specified 
SAEs of concern (e.g., pancreatitis). The Safety Review Officer will not be blinded and will 
confirm or reject the causality determination of the SAE to study intervention. As deemed 
necessa ry, he/she may contact [CONTACT_300148] [INVESTIGATOR_313968]. Any concerns on the part of the Safety Review Officer  may be referred to the DSMB.  
8.[ADDRESS_386579] to the 
investigators and of relevance to the objectives of the study.   
RISE Adult Medication  Protocol   Page 48 
 
 CONFIDENTIAL  9.1  Primary Outcome and A nalyses  
Two  primary outcome s each measurin g ß-cell function  after 3 -months of washout will be 
assessed for this trial. In order to maintain a study -wide =0.05, a closed testing procedure will 
be used to assess the primary outcome [89].   The closed testing procedure is a method of 
hierarchical testing which tests higher -order comparisons before allowing lower -level 
comparisons, thus controlling the type I error and preserv ing power . First, ß-cell function will be 
compared across the four  treatment groups using an analysis of covariance  model adjusted for 
baseline ß-cell function .   From this model, the  overall test of equality across the four  treatment 
groups  will be  comput ed. I f that overall test is significant at the =0.05 level, then each of the 
four possible sets of three interventions will be compared in four separate analysis of 
covariance models. The final significance testing of any set of  two treatment  groups is on ly 
undertaken if the  p-values for each of the  two 3 -intervention tests which include a particular 
two intervention  group  are both p <0.05. For example, for interventions I 1, I2, I3 and I 4, the first 
analysis of variance test I [ADDRESS_386580] is 
significant at the =0.05 level, four separate analysis of covariance models with combinations 
I123, I124, I134 and I 234 are tested. The comparison  I12 is only tested if  both  I123 and I 124 are 
significant at p<0.05  and so forth . The closed testing procedure is chosen  as the primary 
outcome analysis to maintain an overall study -wide =0.05 while preserving power and 
allowing each set of interventions to be compared under pre -specified circumstances . The two 
primary outcomes will be analyzed separately with a t otal type I error probability of 0.05 for 
each, i.e. without an adjustment for two separate outcomes.  
 
Each ANCOVA model will employ White’s robust (information sandwich) estimate of the 
covariance matrix of the model coefficients as the basis for inferenc e [90]. This approach 
preserves power and protects the type 1 error probability when the homoscedastic normal 
errors assumptions are violated.  
9.2  Secondary O utcomes and Analyses  
Comparisons of the primary study outcomes will be made for those with vs. without diabetes at 
study entry, by [CONTACT_545]/ethnicity and sex, by [CONTACT_28007]1c and ß -cell function, and by [CONTACT_314017].  
Analys is of covariance will be us ed to compare the three intervention groups and the placebo 
group for the primary measures of ß-cell function at the end of the active intervention phase 
(12-months) and [ADDRESS_386581] at th e end of the intervention phase (12 -months) and at [ADDRESS_386582] -
washout. As for the primary outcomes, all analyses  will be adjusted for the baseline value of 
each outcome and will use the closed testing procedure described above to preserve a n overall 
=0.05 for those outcomes as well.  
An important secondary analysis of this study is t o determine whether  ß- and -cell function 
from OGTT and fasting samples are sufficiently well correlated with more robust assessments  of 
ß- and -cell function  obtained from the hyperglycemic clamp  to validate their use in large 
clinical trials . For these analyses, Pearson and non -parametric Spearman correlations of simple 
versus sophisticated measures of  ß- and -cell function will be computed. Correlations will  be 
assessed for measures made both on and off therapy . 
Finally, to ex amin e biomarker  associations with glucose metabolism , Pearson and non -
parametric Spearman correlations of each biomarker with ß - and - cell function, insulin 
sensitivity and glucose tolerance measures will be determined. In addition, multiple linear 
regression models will be developed to predict measures of glucose metabolism with the most 
informative biomarker sets.  
9.3 Sample Size/Power Calculations  
There is little preliminary  data on the expected differences in  the primary outcomes  in 
previously drug -naïve patients following a washout . Several 
unpublished analyses provided ranges of possible differences 
between treated and placebo patients, as well as expected 
correlations between baseline and follow up measures. 
Therefore, sample size was based on a minimum effect s ize 
(i.e., absolute difference between any two groups divided by 
[CONTACT_156970]  (SD)) using a  two-sided significance 
level of =0.05 , and a conservative correlation of 0. 57 
between baseline and follow up measures. A sample size of 
56 per arm (224 t otal) at the end of the washout provides 
≥80% power to det ect a minimum effect size of 0.60 between any two treatment groups in 
either of the primary outcome measurements (see Table 3)  for the closed -testing procedure as 
described above using a baseline -adjusted analysis of covariance. A higher effect size will result 
in significantly increased power. A total of 255 participants will be recruited to allow for a 10% 
loss to follow -up over the course of the study.  Table 3 : Power for a sample size of 
224 at end of study (56/treatment 
arm)  
Minimum  
Power  Adjusted 
Effect 
Size Correlation  
84% 0.62 0.60  
81%  0.60 0.57  
77% 0.[ADDRESS_386583] worse function than the participants who 
were measured. This is implemented by [CONTACT_314018], and assigning a lower value (or worst 
rank) to those with missing data [89]. The groups are then compared using a Wilcoxon rank 
test.  
10 DATA PROCESSING AND MANAGEMENT  
10.1   Data Management  System  
Data are entered by [CONTACT_314019]  a web data entry application that directly enters 
study data into the CoC’s study  database . The web application guides the clinical site staff 
member through the data entry process . If an invalid respo nse is entered, the website signals 
and provides a message about the error and how to solve it . At any point during entry, the staff 
member can make an electronic note concerning a particular response . Valid individual 
responses are saved as soon as they are entered . The system includes programmed skip 
patterns as required by [CONTACT_314020], and also includes quality control checks such as 
lists of valid values for multiple choice items . The system provides automated consistency 
checking so the stud y staff can resolve inconsistencies quickly without a lengthy communication 
with the CoC. The same checking is also run on the central database at the CoC to verify that 
centers are resolving consistency checks.  
RISE Adult Medication  Protocol   Page [ADDRESS_386584], and questionable va lues immediately after they are entered . 
Reports with the necessary patient identifying information and the problem values are printed 
and sent to the clinical centers for correction  or verification. When returned, corrected values 
are entered and checked again for consistency with other items . The goals are to make quality 
control a continuous process, to make the turnaround time between error detection and 
correction as short as possible, and to document any changes made to the database.  
10.4  Back -up, Data Se curity and Confidentiality  
The CoC adheres to the George Washington University Biostatistics Center’s data backup and 
security policies to ensure the safety and confidentiality of the data . Backup procedures 
include: twice -weekly system backup, daily incre mental backup, and off -site disaster recovery 
backup . Security procedures include: logon and link password protection, and for internet 
access, separate Web servers which use SSL and encryption algorithms . Virus and malware 
protection software is used on a ll computers and is updated on an hourly basis. All portable 
computers employ full disk encryption. George Washington University computing facilities 
provide support in the event of a disaster . Access to the server and databases is secured by [CONTACT_314021] . Remote access is granted only to authorized users and is 
accomplished using a secure virtual private network (VPN) . Appropriate filtering/firewall setup 
is used to prevent unauthorized access.  
10.5  Tracking S tudy Progress  
The purpo se of tracking reports is to keep the collaborative group informed of study  progress, 
and to report special problems and resolutions . Reports will be  produced regularly by [CONTACT_314006], 
as directed by [CONTACT_40972] . These reports will be  distributed to the study group 
through the study website . 
Tracking reports include the following types of information:  
RISE Adult Medication  Protocol   Page 52 
 
 CONFIDENTIAL   screening and enrollment (versus goal), by [CONTACT_138554], gender, and race/ethnicity  
 tables describing adherence to the study protocol  (attendance at scheduled study visits, 
study intervention compliance)  
 database inventory  
 number of data edit queries generated and outstanding, by [CONTACT_138554]  
 progress of analysis and manuscripts  
10.[ADDRESS_386585] been received and edited, the database will be 
archived in computer readable format, including documentation files, files of  study documents 
(such as forms annotated with variable names, protocols, and manuals o f procedures), data 
files in the form of SAS transport files and input statements, data  dictionaries, and program 
code documenting any derived variables. After the study is complete , all data will be availab le 
to RISE study  investigators  and to investigato rs from outside the study in a manner consistent 
with the NIDDK’s data distribution procedures. Data will be  stored at a readily accessible, 
password -protected web site.  
11  STUDY ADMINISTRATION  
This randomized clinical trial is one of three studies conducted  by [CONTACT_314022] C onsortium. 
RISE is a collaborative study group funded by [CONTACT_300157]  
(NIH) under  a cooperative agreement mechanism . The goal of the RISE  Study  is to test different 
interventions to preserve ß-cell function in separate trials, with shared procedures and data 
collection approaches allowing for the ability to compare data across studies and combine data 
from individual studies by [CONTACT_314023]. The RISE Study 
inves tigators will be conducting three separate clinical trials. The investigators for each trial are 
responsible for recruiting participants and implementing their respective protocols. In addition, 
the RISE  Study  investigators participate in consortia activit ies, as described below.  
11.1  Organization  
The major organizational components and their responsibilities are described:  
 The RISE Steering Committee , comprised  of the principal investigators of the clinical centers, 
the CoC, and the NIDDK project office, is t he primary decision making body for the study 
with overall responsibility for the design and conduct of the common elements of the study 
protocols.  
 The NIDDK project office  participates in all decision -making activities and selects and 
oversees the activit ies of the DSMB . 
RISE Adult Medication  Protocol   Page 53 
 
 CONFIDENTIAL   The Coordinating Center  (CoC) located at the George Washington University Biostatistics 
Center operates under subcontract to the Seattle Institute for Biomedical and Clinical 
Research  (SIBCR). The CoC  has responsibility for coordinating th e study, including 
production and distribution of materials and documents, set -up and administration of the 
data management system, maintenance of the central database, analysis of primary study 
results, distribution of final study data to the clinical cen ters and NIDDK repository, and 
reporting of results in collaboration with the other investigators.  
 The Central Blood Laboratory (CBL) operates under subcontract to the Seattle Institute for 
Biomedical and Clinical Research. The CBL is responsible for provi ding procedures for the 
handling, storage, and shipment of blood specimens, for performing the tests and assays, 
for performing quality control, for providing patient -level reports to clinical centers, and for 
transferring results to the CoC. 
 The DSMB  is composed of outside experts in the design and conduct of clinical trials, and in 
type [ADDRESS_386586] is responsible for reviewing the study documents, monitoring 
study progress, and monitoring patient safety .  
 Working committees  include Outcomes , Recruitment and Retention, Safety and Monitoring, 
Publications and Presentations, Ancillary Studies, Lab Quality Control, and Program 
Coordinators. Committees can be discontinued and additional committees can be created 
as required.  
11.2   Central Laboratorie s and Reading Centers  
In collaboration with the CoC and study investigators, central laboratories and reading ce nters 
perform the following tasks:  
1. Establish procedures and standards for training staff involved in the measurement, 
collection, preparation, h andling, transfer, and all other procedures and processes . 
2. Conduct training sessions and contribute training materials to the study manuals of 
procedures.  
3. Provide or facilitate the acquisition of equipment and materials, including specifying brands, 
sizes, and suppliers as applicable.  
4. Establish procedures for data entry and transfer of data to CoC.  
5. Develop procedures for the internal as well as external qua lity control, and provide periodic 
reports on the quality control surveillance.  
6. Provide long -term storage of reserve specimens or materials as directed by [CONTACT_314024] . 
RISE Adult Medication  Protocol   Page 54 
 
 CONFIDENTIAL   
Each director represen ts the laboratory or center at RISE Steering Committee meetings, on 
Steering Committee conference calls, and on other conference calls where the director’s 
participation is deemed necessary.  
11.[ADDRESS_386587] pass certification 
criteria, including satisfactory participation in training as above, and supplying the CoC with an 
IRB approval letter and stamped informed consent forms . 
Throughout the study, new staff will be trained at the appropriate clinical center and by [CONTACT_300160] . Clinic staff will re -certify annually on identified procedures . Records of 
certificat ions and training will be maintained at the clinical sites . 
11.4   Site Visits   
The Steering Committee will be responsible for ongoing monitoring of the performance of study 
components.  
There are  two types of site visits that can be conducted  (1) scheduled moni toring and (2) as 
needed to address specific problems.  
The RISE S tudy does not anticipate scheduled monitoring site visits . 
If necessary, site visits will be conducted to address specific problems at a clinical center. 
Depending on the specific issues, si te visits will be attended by [CONTACT_314025], the 
NIDDK project office, the CoC, clinical center coordinators, and others as needed.  Each visit will 
follow a predetermined format and site visitors will complete a checklist to record findings . The 
site visit team will review study procedures and compare data collection records to listings from 
the central database. A formal site visit report will be provided to the clinical center and to the 
RISE Adult Medication  Protocol   Page [ADDRESS_386588] 
combination for access . The web server utilizes the Secure Socket Layer (SSL ) protocol that 
encrypts all traffic to and from the server . Investigators, coordinators, consultants, and other 
study staff who would benefit from access to the information on the website are each given a 
unique user ID and password, which identifies the user to the web server and can be used to 
restrict access to particular web pages if desired.  
The website contains study documents such as the protocol, manual of procedures, and forms, 
study calendar, directory, meeting and conference call information, li nks to other sites, tracking 
reports, minutes, and agendas . 
11.[ADDRESS_386589] each in dividual’s reputation and career from potentially embarrassing or 
harmful allegations of inappropriate behavior, and to  protect the integrity of RISE S tudy 
research . Conflict of interest forms are kept on file at the CoC, and all conflicts are declared at 
each study group meeting.  
The RISE Ethics Committee ( NIDDK Project Scientist, NIDDK Program Official and study group 
member ) determine s (1) if the disclosed interests could directly and significantly affect the 
performance of study responsibilities and (2)  the actions needed for management, reduction, 
or elimination of the conflict . In addition to complying with the RISE conflict of interest policies, 
collaborators must certify to the Ethics Committee that they have complied with all of their 
local and inst itutional requirements regarding conflict of interest and disclosure . This is 
accomplished by [CONTACT_314026][INVESTIGATOR_313969](s). Should a n institution make a determination regarding an 
investigator’s potential conflict of interest that could affect participation in RISE, the local clinic 
should report this to the RISE Executive  Committee.  
RISE Adult Medication  Protocol   Page 56 
 
 CONFIDENTIAL  11.7   Publications and Presentations Policy   
The Publications and Presentations Subcommittee (PPS) will co ordinate, monitor, review, and 
assume responsibility for overseeing the preparation of all study -wide communications (press 
releases, interviews, presentations (oral and posters), and publications) relating to the scientific 
aspects of the study . There will be no publication or presentation of study plans or results, 
including ancillary studies, which have not been reviewed and approved by a majority of the 
PPS, and for some types of communications, a majority of the Steering Committee.   
With respect to publications and presentations from the RISE  Study  consortium, the goals of 
the PPS are to:  
1. Ensure accurate, uniform, timely, and high quality reporting of RISE activities and 
results;  
2. Preserve the scientific integrity of the study;  
3. Safeguard the rights and confidentiality of participants;  
4. Assure that the timing of publications and presentations serves the right of the public 
to know the results of the program without jeopardizing its conduct ; and  
5. Ensure that appropriate credit is acknowledge d for people responsible for RISE and 
the data being reported and for the funding organizations.  
Detailed policies are found in the Manual of Operations.  
11.8   Ancillary Studies  Policy   
The Ancillary Studies Subcommittee will evaluate all proposals for studies  that involve RISE 
participants and/or data that are not a part of the protocol . These studies may be done in all 
RISE participants or only on a subset of participants in RISE . Ancillary studies may make use of 
data and/or samples already collected from RI SE participants or may involve the collection of 
new data and/or samples . The RISE Ancillary Studies Subcommittee  must review all proposed 
ancillary studies  and these must receive final approval by [CONTACT_314027]. Major factors in con sideration of ancillary studies will include:  
 Clinical importance and scientific validity ; 
 Compatibility of goals with those of RISE ; and  
 Burden on study subjects and  staff, including those at the CoC  
RISE Adult Medication  Protocol   Page [ADDRESS_386590] to obtain funding from outside the study.  
11.9   Protocol Amendments  
Adoption of protocol amendments requires two -thirds majority approval by [CONTACT_314028] . The amended protocol will be  
resubmitted to the IRB, and the participant consent will be  revised appropriately.  
11.10  Repository for Storage and Distribution of RISE Data and 
Samples  
At the end of the study, de -identified  research data and samples of blood and urine will be 
provided to the NIDDK Central Repositories, a research resource supported by [CONTACT_66121]. The Repository collects, stores, and distributes biological samples and 
associated data fr om people with many kinds of disorders, from unaffected family members, 
and from other healthy people . The purpose of this collection is to make samples available for 
use in research for the study of obesity and diabetes and related complications after the  RISE 
Study is completed. Sending samples to the Repository may give scientists valuable research 
material that can help them to develop new diagnostic tests, new treatments, and new ways to 
prevent or postpone the onset of obesity and/or diabetes.  
As a component of the informed consent process, a ll participants will be asked to provide 
specific informed consent for release of data and samples to the NIDDK Repositories. Before 
the RISE Study investigators  send data or samples to the Repository, each sampl e and data 
record will be given a code number and the data will be de -identified according to HIPAA 
requirements . Participants may choose to participa te in RISE but not provide consent to have 
their samples and/or data transferred to the NIDDK Repository.  
[ADDRESS_386591] been obtained (DSMB, FDA, IRBs, CTAs or CRADAs), central study 
training  has been performed and all study medications an d supplies have been procured. 
Intervention and washout phases occur through the middle of year 5 and presentations and 
publications throughout the period of the study.  
RISE Adult Medication  Protocol   Page 58 
 
 CONFIDENTIAL  13  LITERATURE CITED  
[1] Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin 
resistance and type 2 diabetes. Nature 444: 840 -846 
[2] Dunning BE, Gerich JE (2007) The role of α -cell dysregulation in fasting and postprandial 
hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Re v 28: 253 -283 
[3] Garvey WT, Olefsky JM, Griffen J, Hamman RF, Kolterman OG (1985) The effect of insulin 
treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34: 222 -
234 
[4] Ilkova H, Glaser B, Tunckale A, Bagriacik N, C erasi E (1997) Induction of long -term 
glycemic control in newly diagnosed type 2 diabetic patients by [CONTACT_314029]. Diabetes Care 20: 1353 -1356  
[5] Weng J, Li Y, Xu W, et al. (2008) Effect of intensive insulin therapy on beta -cell function 
and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre 
randomised parallel -group trial. Lancet 371: 1753 -1760  
[6] The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of 
type 2 diabetes wi th lifestyle intervention or metformin. N Engl J Med 346: 393 -403 
[7] Kahn SE, Haffner SM, Heise MA, et al. (2006) Glycemic durability of rosiglitazone, 
metformin, or glyburide monotherapy. N Engl J Med 355: 2427 -2443  
[8] Kahn SE, Lachin JM, Zinman B, et a l. (2011) Effects of rosiglitazone, glyburide and 
metformin on ß -cell function and insulin sensitivity in ADOPT. Diabetes 60: 1552 -1560  
[9] Fehse F, Trautmann M, Holst JJ, et al. (2005) Exenatide augments first - and second -
phase insulin secretion in respon se to intravenous glucose in subjects with type 2 diabetes. J 
Clin Endocrinol Metab 90: 5991 -5997  
[10] Drucker DJ, Nauck MA (2006) The incretin system: glucagon -like peptide -1 receptor 
agonists and dipeptidyl peptidase -4 inhibitors in type 2 diabetes. Lanc et 368: 1696 -1705  
[11] Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national 
estimates and general information on diabetes and prediabetes in the [LOCATION_002], 2011. 
Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf , accessed 2/13/2011 
2011  
RISE Adult Medication  Protocol   Page 59 
 
 CONFIDENTIAL  [12] American Diabetes Association (1997) Report of the Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus. Diabetes Care 20: 118 3-1197  
[13] International Expert Committee (2009) International Expert Committee report on the 
role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32: 1327 -1334  
[14] Tuomilehto J, Lindstrom J, Eriksson JG, et al. (2001) Prevention of type 2 d iabetes 
mellitus by [CONTACT_258656]. N Engl J Med 
344: 1343 -1350  
[15] The DREAM Trial Investigators (2006) Effect of rosiglitazone on the frequency of 
diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised 
controlled trial. Lancet 368: 1096 -1105  
[16] Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V (2006) The 
Indian Diabetes Prevention Programme shows that lifestyle modification and metformin 
preve nt type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP -1). 
Diabetologia 49: 289 -297 
[17] [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group (1998) Intensive blood -glucose control 
with sulphonylureas or insulin compared with conventional  treatment and risk of complications 
in patients with type 2 diabetes ([LOCATION_006]PDS 33). Lancet 352: 837 -853 
[18] Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association 
GENNID Study Group (2002) ß -cell function is the major determinant of  oral glucose tolerance 
in four ethnic groups in the [LOCATION_002]. Diabetes 51: 2170 -2178  
[19] The Diabetes Prevention Program Research Group (2005) Role of insulin secretion and 
sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention P rogram: effects of 
lifestyle intervention and metformin. Diabetes 54: 2404 -2414  
[20] Kahn SE, Zraika S, Utzschneider KM, Hull RL (2009) The beta cell lesion in type 2 
diabetes: there has to be a primary functional abnormality. Diabetologia 52: 1003 -1012  
[21] Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin 
secretory dysfunction and insulin resistance in the pathogenesis of type [ADDRESS_386592] 104: 787 -794 
[22] Utzschneider KM, Prigeon RL, Faulenbach MV, et a l. (2009) Oral disposition index 
predicts the development of future diabetes above and beyond fasting and 2 -h glucose levels. 
Diabetes Care 32: 335 -341 
RISE Adult Medication  Protocol   Page 60 
 
 CONFIDENTIAL  [23] Poitout V, Robertson RP (2008) Glucolipotoxicity: fuel excess and ß -cell dysfunction. 
Endocr Rev 29 : 351 -366 
[24] Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU (1985) Islet pathology and the 
pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4: 110 -125 
[25] Butler AE, Janson J, Bonner -Weir S, Ritzel R, Rizza RA, B utler PC (2003) ß -cell deficit and 
increased ß -cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102 -110 
[26] Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic ß -cell mass in 
European subjects with type 2 diabetes. Diabetes Obes Metab 10 (Suppl 4): 32 -42 
[27] Hull RL, Westermark GT, Westermark P, Kahn SE (2004) Islet amyloid: a critical entity in 
the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89: 3629 -3643  
[28] Unger RH, Aguilar -Parada E, Muller WA, Eisentraut AM (1970) Studies of pancreatic 
alpha cell function in normal and diabetic subjects. J Clin Invest 49: 837 -848 
[29] Muller WA, Faloona GR, Aguilar -Parada E, Unger RH (1970) Abnormal alpha -cell function 
in diabetes. Response to carbohydrate and protein inge stion. N Engl J Med 283: 109 -115 
[30] Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D, Jr (1984) Diminished B cell 
secretory capacity in patients with noninsulin -dependent diabetes mellitus. J Clin Invest 74: 
1318 -1328  
[31] Mitrakou A, Kelley D, Mokan  M, et al. (1992) Role of reduced suppression of glucose 
production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 
326: 22 -29 
[32] Larsson H, Berglund G, Ahren B (1995) Glucose modulation of insulin and glucagon 
secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab 80: 1778 -1782  
[33] Kirk RD, Dunn P, Smith JR, Beaven DW, Donald RA (1975) Abnormal pancreatic alpha -cell 
function in first -degree relatives of known diabetics. J Clin Endocrinol Metab 40: 91 3-916 
[34] Tasali E, Mokhlesi B, Van Cauter E (2008) Obstructive sleep apnea and type 2 diabetes: 
interacting epi[INVESTIGATOR_7509]. Chest 133: 496 -506 
[35] Seicean S, Kirchner HL, Gottlieb DJ, et al. (2008) Sleep -disordered breathing and 
impaired glucose metabolism i n normal -weight and overweight/obese individuals: the Sleep 
Heart Health Study. Diabetes Care 31: 1001 -1006  
RISE Adult Medication  Protocol   Page 61 
 
 CONFIDENTIAL  [36] Resnick HE, Redline S, Shahar E, et al. (2003) Diabetes and sleep disturbances: findings 
from the Sleep Heart Health Study. Diabetes Care 26: 7 02-709 
[37] Foster GD, Sanders MH, Millman R, et al. (2009) Obstructive sleep apnea among obese 
patients with type 2 diabetes. Diabetes Care 32: 1017 -1019  
[38] Aronsohn RS, Whitmore H, Van Cauter E, Tasali E (2010) Impact of untreated obstructive 
sleep apn ea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 181: 507 -513 
[39] The Diabetes Prevention Program Research Group (2005) Prevention of type 2 diabetes 
with troglitazone in the Diabetes Prevention Program. Diabetes 54: 1150 -1156  
[40] DeFr onzo RA, Tripathy D, Schwenke DC, et al. (2011) Pi[INVESTIGATOR_313970]. N Engl J Med 364: 1104 -1115  
[41] Buchanan TA, Xiang AH, Peters RK, et al. (2002) Preservation of pancreatic beta -cell 
function and preventio n of type 2 diabetes by [CONTACT_314030] -risk hispanic women. Diabetes 51: 2796 -2803  
[42] Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for 
prevention of type 2 diabetes mellitus: the  STOP -NIDDM randomised trial. Lancet 359: 2072 -
2077  
[43] The NAVIGATOR Study Group (2010) Effect of nateglinide on the incidence of diabetes 
and cardiovascular events. N Engl J Med 362: 1463 -1476  
[44] The ORIGIN Trial Investigators (2012) Basal insulin and  cardiovascular and other 
outcomes in dysglycemia. N Engl J Med 367: 319 -328 
[45] Zinman B, Harris SB, Neuman J, et al. (2010) Low -dose combination therapy with 
rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double -blind 
randomised controlled study. Lancet 376: 103 -111 
[46] Lindstrom J, Ilanne -Parikka P, Peltonen M, et al. (2006) Sustained reduction in the 
incidence of type 2 diabetes by [CONTACT_279278]: follow -up of the Finnish Diabetes 
Prevention Study. Lancet 368:  1673 -1679  
[47] DREAM On Investigators (2011) Long -term effect of rosiglitazone and/or ramipril on the 
incidence of diabetes. Diabetologia 54: 487 -495 
[48] The DREAM Trial Investigators (2011) Incidence of diabetes following ramipril or 
rosiglitazone withd rawal. Diabetes Care 34: 1265 -1269  
RISE Adult Medication  Protocol   Page 62 
 
 CONFIDENTIAL  [49] [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group (1998) Effect of intensive blood -glucose 
control with metformin on complications in overweight patients with type 2 diabetes ([LOCATION_006]PDS 
34). Lancet 352: 854 -865 
[50] [LOCATION_006] Prospec tive Diabetes Study ([LOCATION_006]PDS) Group (1995) U.K. Prospective Diabetes Study 
16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44: 1249 -
1258  
[51] Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H (2012) Pi[INVESTIGATOR_313971]: a population -based cohort study. 
Diabetologia 55: 1953 -1962  
[52] Azoulay L, Yin H, Filion KB, et al. (2012) The use of pi[INVESTIGATOR_313972] 2 diabe tes: nested case -control study. BMJ 344: e3645  
[53] Farilla L, Bulotta A, Hirshberg B, et al. (2003) Glucagon -like peptide 1 inhibits cell 
apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 
144: 5149 -5158  
[54] Xu G, Stoffers DA, Habener JF, Bonner -Weir S (1999) Exendin -4 stimulates both ß -cell 
replication and neogenesis, resulting in increased ß -cell mass and improved glucose tolerance 
in diabetic rats. Diabetes 48: 2270 -2276  
[55] Bunck MC, Diamant M, Corner A, et al. (2009) One -year treatment with exenatide 
improves ß -cell function, compared to insulin glargine, in metformin treated type 2 diabetes 
patients: a randomized, controlled trial. Diabetes Care 32: 762 -768 
[56] Bunck MC, Corner A, Eliasson B, et al. (2010)  Three -year exenatide therapy, followed by 
a 4-week off -drug period, had a sustainable effect on ß -cell disposition index in metformin 
treated patients with type 2 diabetes patients. Diabetes 59 (Suppl 1): A198  
[57] Bailey CJ, Turner RC (1996) Metformin. N  Engl J Med 334: 574 -579 
[58] Hemmingsen B, Christensen LL, Wetterslev J, et al. (2012) Comparison of metformin and 
insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials 
with meta -analyses and trial sequential an alyses. BMJ 344: e1771  
[59] Triplitt C, Glass L, Miyazaki Y, et al. (2006) Comparison of glargine insulin versus 
rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus 
sulfonylurea. Diabetes Care 29: 2371 -2377  
RISE Adult Medication  Protocol   Page 63 
 
 CONFIDENTIAL  [60] Currie CJ , Poole CD, Gale EA (2009) The influence of glucose -lowering therapi[INVESTIGATOR_313973] 2 diabetes. Diabetologia 52: 1766 -1777  
[61] Sisson EM (2011) Liraglutide: clinical pharmacology and considerations for therapy. 
Pharmacotherapy 31: 896 -911 
[62] Drucker DJ, Sherman SI, Bergenstal RM, Buse JB (2011) The safety of incretin -based 
therapi[INVESTIGATOR_014] --review of the scientific evidence. J Clin Endocrinol Metab 96: 2027 -2031  
[63] Noel RA, Braun DK, Patterson RE, Bloomgren GL (2009) Increased risk of acute 
pancreat itis and biliary disease observed in patients with type 2 diabetes: a retrospective 
cohort study. Diabetes Care 32: 834 -838 
[64] Mitrakou A, Vuorinen -Markkola H, Raptis G, et al. (1992) Simultaneous assessment of 
insulin secretion and insulin sensitivity u sing a hyperglycemia clamp. J Clin Endocrinol Metab 
75: 379 -382 
[65] Brunzell JD, Robertson RP, Lerner RL, et al. (1976) Relationships between fasting plasma 
glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol  
Metab 42: 222 -229 
[66] Kanat M, Mari A, Norton L, et al. (2012) Distinct ß -cell defects in impaired fasting 
glucose and impaired glucose tolerance. Diabetes 61: 447 -453 
[67] Vilsboll T, Brock B, Perrild H, et al. (2008) Liraglutide, a once -daily human GLP -1 
analogue, improves pancreatic B -cell function and arginine -stimulated insulin secretion during 
hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 25: 152 -156 
[68] Johnston C, Ward WK, Beard JC, McKnight B, Porte D, Jr (1990) Islet func tion and insulin 
sensitivity in the non -diabetic offspring of conjugal type 2 diabetic patients. Diabet Med 7: 119 -
125 
[69] Kahn SE, Prigeon RL, McCulloch DK, et al. (1993) Quantification of the relationship 
between insulin sensitivity and ß -cell function in human subjects.  Evidence for a hyperbolic 
function. Diabetes 42: 1663 -1672  
[70] Ahren B (2006) Glucagon secretion in relation to insulin sensitivity in healthy subjects. 
Diabetologia 49: 117 -122 
[71] Larsson H, Ahren B (1996) Islet dysfunction in obese  women with impaired glucose 
tolerance. Metabolism 45: 502 -509 
RISE Adult Medication  Protocol   Page 64 
 
 CONFIDENTIAL  [72] Burns SF, Bacha F, Lee SJ, Tfayli H, Gungor N, Arslanian SA (2011) Declining ß -cell 
function relative to insulin sensitivity with escalating OGTT 2 -h glucose concentrations in the 
nondiabe tic through the diabetic range in overweight youth. Diabetes Care 34: 2033 -2040  
[73] Schwartz B, Jacobs DR, Jr., Moran A, Steinberger J, Hong CP, Sinaiko AR (2008) 
Measurement of insulin sensitivity in children: comparison between the euglycemic -
hyperinsul inemic clamp and surrogate measures. Diabetes Care 31: 783 -788 
[74] Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and 
oral glucose tests for assessment of ß -cell function: modeling analysis in normal subjects. Am J 
Physiol Endocrinol Metab 283: E1159 -E1166  
[75] Cobelli C, Toffolo GM, Dalla Man C, et al. (2007) Assessment of ß -cell function in 
humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and 
oral glucose tests. Am J Physiol End ocrinol Metab 293: E1 -E15 
[76] Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates 
from C -peptide levels. Comparison of individual and standard kinetic parameters for C -peptide 
clearance. Diabetes 41: 368 -377 
[77] Utzschneider KM, Prigeon RL, Tong J, et al. (2007) Within -subject variability of measures 
of beta cell function derived from a 2 h OGTT: implications for research studies. Diabetologia 
50: 2516 -2525  
[78] Lyons TJ, Basu A (2012) Biomarkers in diabetes: hemogl obin A1c, vascular and tissue 
markers. Translational research : the journal of laboratory and clinical medicine 159: 303 -312 
[79] Mather KJ, Funahashi T, Matsuzawa Y, et al. (2008) Adiponectin, change in adiponectin, 
and progression to diabetes in the Diab etes Prevention Program. Diabetes 57: 980 -986 
[80] Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: 
a systematic review and meta -analysis. JAMA 302: 179 -188 
[81] Salomaa V, Havulinna A, Saarela O, et al. (2010) Thir ty-one novel biomarkers as 
predictors for clinically incident diabetes. PLoS One 5: e10100  
[82] Kolberg JA, Jorgensen T, Gerwien RW, et al. (2009) Development of a type 2 diabetes 
risk model from a panel of serum biomarkers from the Inter99 cohort. Diabete s Care 32: 1207 -
1212  
[83] Akirav EM, Lebastchi J, Galvan EM, et al. (2011) Detection of beta cell death in diabetes 
using differentially methylated circulating DNA. Proc Natl Acad Sci U S A 108: [ZIP_CODE] -[ZIP_CODE]  
RISE Adult Medication  Protocol   Page 65 
 
 CONFIDENTIAL  [84] Karnik SK, Chen H, McLean GW, et al. (2007) Menin controls growth of pancreatic beta -
cells in pregnant mice and promotes gestational diabetes mellitus. Science 318: 806 -809 
[85] Park S, Kim da S, Daily JW, Kim SH (2011) Serum prolactin concentrations determine 
whether they improve or impair beta -cell function and insulin sensitivity in diabetic rats. 
Diabetes Metab Res Rev 27: 564 -574 
[86] Marina AL, Utzschneider KM, Wright LA, Montgomery BK, Marcovina SM, Kahn SE 
(2012) Colesevelam improves oral but not intravenous glucose tolerance by a mec hanism 
independent of insulin sensitivity and beta -cell function. Diabetes Care 35: 1119 -1125  
[87] Ota A, Wang Y (2012) Cdc37/Hsp90 protein -mediated regulation of IRE1alpha protein 
activity in endoplasmic reticulum stress response and insulin synthesis in INS-1 cells. J Biol 
Chem 287: 6266 -6274  
[88] Bang H, Edwards AM, Bomback AS, et al. (2009) Development and validation of a patient 
self-assessment score for diabetes risk. Annals of internal medicine 151: 775 -783 
[89] Lachin JM (1999) Worst -Rank Score Anal ysis with Informatively Missing Observations in 
Clinical Trials. Controlled Clinical Trials 20: 408 -422 
[90] White H (1980) Heteroskedasticity -consistent covariance matrix estimator and a direct 
test for heteroskedasticity.  Econometrics 48: 817 –838 
 
 
 